Launching New Products in the Finnish Pharmaceutical Industry : A Relationship Approach by Matikainen, Minna
?  
Division of Pharmaceutical Chemistry and Technology  
Faculty of Pharmacy 
University of Helsinki 
Finland 
 
 
 
 
Launching New Products  
in the Finnish Pharmaceutical Industry:  
A Relationship Approach  
 
 
by 
 
 
Minna Matikainen 
 
 
 
 
ACADEMIC DISSERTATION 
 
 
 
 
To be presented, with the permission of the Faculty of Pharmacy of the University of 
Helsinki, for public examination in Small hall (4050) of the main building 
(Fabianinkatu 33, Helsinki) on December 11th 2015, at 12:00 noon. 
 
Helsinki 2015 
?Supervisors Professor Anne Juppo 
Division of Pharmaceutical Chemistry and Technology  
  Faculty of Pharmacy 
  University of Helsinki 
  Finland 
 
Professor Petri Parvinen 
Strategic Marketing and Management 
  Department of Forest Sciences 
  Faculty of Agriculture and Forestry 
University of Helsinki 
  Finland 
 
  Ph.D. (Pharm.) Marikki Peltoniemi 
  Division of Pharmaceutical Chemistry and Technology  
Faculty of Pharmacy 
  University of Helsinki 
  Finland 
 
Reviewers Assistant Professor Stefan Fraenkel 
Stockholm Business School 
Stockholm University 
  Sweden 
 
Senior Vice President 
Swedish Orphan Biovitrum AB 
 
 
Professor Arto Rajala 
Department of Marketing 
  Faculty of Business Studies 
  University of Vaasa 
  Finland 
 
Opponent Adjuct Professor Paula Rytilä, MD, PhD 
  University of Helsinki 
  Finland 
 
Medical Director 
Orion Corporation Orion Pharma 
 
© Minna Matikainen 2015 
ISBN 978-951-51-1736-6 (Paperback) 
ISBN 978-951-51-1737-3 (PDF) 
ISSN 2342-3161 (Print) 
ISSN 2342-317X (Online) 
 
Hansaprint Oy 
Helsinki 2015 
?  
  
? i 
Abstract 
?
Matikainen MM., 2015. Launching New Products in the Finnish Pharmaceutical 
Industry: A Relationship Approach 
 
Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis 
Helsinkiensis, 99/2015, pp. 242 
ISBN 978-951-51-1736-6 (Paperback), ISBN 978-951-51-1737-3 (PDF, 
http://ethesis.helsinki.fi), ISSN 2342-3161 (Print), ISSN 2342-317X (Online) 
 
Successful product launches are a critical driver of a company’s performance. 
The prevailing literature on the launch of new products has mainly concentrated on a 
product’s superiority compared to that of its competitors as well as the strategic and 
tactical launch activities. Studies on the strategic orientations of companies have 
generally focused on customers and competitors by predicting the launch performance 
through the concept of market orientation. However, the existing literature on new 
product launch has largely omitted the importance of customer relationships, although 
relationship marketing has been one of the dominant paradigms in industrial marketing 
research. Thus, the concept of relationship orientation, which emphasizes the 
importance of customer relationships, offers a fruitful research setting because it 
complements the dominant new product launch approaches.  
The pharmaceutical industry places a heavy emphasis on research and 
development and has a vital reliance on successful product launches. However, the 
literature on pharmaceutical new product launches is fragmented, and there is currently 
a lack of holistic overviews on the key determinants of what makes a successful launch. 
Thus, the aim of this thesis is to provide a comprehensive overview on the role and 
impact of the key determinants of a successful new product launch in the 
pharmaceutical industry, focusing especially on the aspects of relationships from the 
perspectives of both buyers and sellers. In practice, this study considers the extent to 
which a new product launch and getting physicians’ to prescribe a new drug is relational 
activity. It also examines the phase of the launch process in which relational activities 
should be used and how they should be conducted in order to maximize the launch 
performance.  
The role and relative impact of a company’s strategic orientations and their 
mediating mechanisms were studied with survey data collected from the pharmaceutical 
companies operating in Finland. Partial least squares path modeling revealed that the 
relationship orientation had the strongest positive impact on both customer acceptance 
and on the financial success of a launch when compared to market orientation and 
product orientation. It was found that a company’s accumulated market-based assets 
represented an alternative mediator in addition to the widely studied concept of product 
advantage. Furthermore, it was shown that sales force management and relationship 
marketing activities transformed a relationship-oriented organizational culture into 
launch performance. 
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The partial least squares regression modeling combined with target projection 
helped to identify the diversity of determinants affecting launch performance. It was 
found that product advantage and relationship marketing activities contributed to 
gaining the acceptance of key opinion leaders in the early phase of launch, while 
market-based assets and a company’s relationship orientation largely determined the 
acceptance of the majority of target customers in the later phase. Both strategic choices 
and tactical decisions drove the financial success of a new product launch. 
The buyer’s perspective focused on the physician-pharmaceutical industry 
relationship and how this affected the introduction of a new product. The relationship 
was studied by means of theme-interviews among a randomized sample of physicians. 
The positive relationship orientation of the physicians toward the pharmaceutical 
industry and whether they actively interacted with pharmaceutical companies were 
reflected in their early adoption of new drugs, especially when a product had a unique 
advantage and the physician’s own personal interest accelerated the adoption of a new 
drug. In comparison, physicians who were negatively oriented to the pharmaceutical 
industry and interacted with it in a passive way adopted the use of a new drug later and 
did so based on evidence- and experience-based reasoning and the opinions of 
colleagues. 
In conclusion, this thesis calls for a relationship approach in order to 
complement the traditional sales and marketing approach regarding the launch of new 
pharmaceutical products. A successful pharmaceutical product launch should focus on 
appropriate relationship marketing activities that are conducted in a timely manner to 
achieve customer acceptance and financial launch performance.  
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Onnistunut tuotelanseeraus on kriittinen edellytys yrityksen menestymiselle. 
Vallitseva uuden tuotteen lanseeraukseen liittyvä kirjallisuus on keskittynyt pääasiassa 
tuotteen ylivertaisuuteen sen kilpailijoihin verrattuna sekä strategisiin ja taktisiin 
lanseerausaktiviteetteihin. Yrityksen strategisia orientaatioita koskevat tutkimukset ovat 
korostaneet yleistä asiakas- ja kilpailijafokusta ennustaen lanseerauksessa onnistumista 
markkinaorientaatio-käsitteen avulla. Nykyinen uuden tuotteen lanseerauskirjallisuus on 
kuitenkin pitkälti sivuuttanut asiakassuhteiden merkityksen, vaikka suhdemarkkinointi 
on yksi vallitsevista suuntauksista teollisen markkinoinnin tutkimuksessa. Tämän 
vuoksi asiakassuhteiden tärkeyttä korostava suhdeorientaatio tarjoaa hedelmällisen 
tutkimuspohjan täydentäen vallitsevia uuden tuotteen lanseeraukseen liittyviä 
näkökumia. 
Lääketeollisuus painottaa voimakkaasti tutkimusta ja tuotekehitystä ja on 
riippuvainen onnistuneista tuotelanseerauksista. Uusien lääkkeiden lanseeraukseen 
liittyvä kirjallisuus on kuitenkin pirstaloitunutta, eikä lanseerauksen onnistumiseen 
vaikuttavista keskeisistä tekijöistä ole voitu muodostaa kokonaiskuvaa aikaisemmin. 
Tämän tutkielman tarkoituksena on saada kattava yleiskuva eri tekijöiden roolista ja 
vaikutuksesta uuden tuotteen lanseerauksen onnistumiseen lääketeollisuudessa 
keskittyen erityisesti suhdenäkökulmaan sekä myyjän että ostajan kannalta. 
Käytännössä tutkimuksessa on kyse siitä, missä määrin lääkkeiden lanseeraaminen ja 
lääkärien saaminen määräämään uutta lääkettä on suhdetoimintaa ja missä 
lanseerausprosessin vaiheessa ja miten suhdetoimintaan liittyviä aktiviteetteja tulisi 
harjoittaa lääkelanseerauksen onnistumisen todennäköisyyden maksimoimiseksi.  
Yrityksen strategisten orientaatioiden roolia ja suhteellista vaikutusta sekä 
niiden välittäviä mekanismeja tutkittiin kyselytutkimuksessa kerätyllä aineistolla 
Suomessa toimivista lääkeyrityksistä. Partial least squares –polkumallinnus osoitti, että 
suhdeorientaatiolla oli suurin positiivinen vaikutus sekä asiakashyväksyntään että 
lanseerauksen taloudelliseen onnistumiseen markkina- ja tuoteorientaatioihin 
verrattuna. Tutkimus osoitti, että laajasti tutkitun tuote-edun lisäksi yritykselle kertyneet 
markkinapohjaiset edut sekä myyntihenkilöstön johtaminen ja suhdemarkkinointi-
aktiviteetit välittävät suhdeorientaatiota korostavan organisaatiokulttuurin muuntumista 
onnistuneeksi lanseeraukseksi.  
Lisäksi partial least squares –regressiomallinnus yhdistettynä target projection –
menetelmään tunnisti lanseerauksen onnistumiseen vaikuttavien menestystekijöiden 
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monimuotoisuuden. Tuote-etu ja suhdemarkkinointi-aktiviteetit vaikuttavat keskeisten 
mielipidevaikuttajien hyväksynnän saavuttamiseen lanseerauksen varhaisessa vaiheessa, 
kun taas markkinapohjainen pääoma ja yrityksen suhdeorientaatio määrittävät pitkälti 
pääasiallisten kohdeasiakkaiden hyväksynnän myöhemmässä vaiheessa. Strategiset 
valinnat ja taktiset päätökset puolestaan vaikuttavat uuden tuotteen lanseerauksen 
taloudelliseen onnistumiseen. 
Tutkimus tarkasteli lääkärin ja lääketeollisuuden välistä suhdetta ja sen 
heijastumista uuden lääkkeen käyttöönotossa teemahaastattelututkimuksessa 
satunnaisotannalla valittujen lääkärien joukossa. Lääkärien positiivinen 
suhdeorientaatio lääketeollisuutta kohtaan ja aktiivinen vuorovaikutus lääkeyritysten 
kanssa heijastuivat varhaisena uuden lääkkeen käyttöönottona, jossa tuote-etu ja 
lääkäreiden henkilökohtainen kiinnostus nopeuttivat uuden lääkkeen omaksumista. Sen 
sijaan negatiivisesti orientoituneet ja passiivisesti vuorovaikutuksessa olleet lääkärit 
ottivat uuden lääkkeen käyttöönsä myöhemmin lääkkeeseen liittyvän tutkimusnäytön ja 
käyttökokemuksen sekä kollegoiden mielipiteiden perusteella. 
Yhteenvetona tämä tutkimus täydentää perinteistä myynti- ja 
markkinointilähestymistapaa suhdenäkökulmalla uuden tuotteen lanseerauksessa 
lääketeollisuudessa. Onnistuneessa lääkelanseerauksessa tulisi keskittyä 
tarkoituksenmukaisiin ja oikea-aikaisesti toteutettuihin suhdemarkkinointi-
aktiviteetteihin asiakashyväksynnän ja lanseerauksen taloudellisen menestyksen 
saavuttamiseksi. 
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1 Introduction 
?
1.1 Motivation for the study 
 
New product launch (NPL) means bringing a product to the market for the first 
time (Beard and Easingwood, 1996; Crawford and Di Benedetto, 2011). The aim of a 
product launch is to maximize the chances of a company’s profitability achieving a 
product’s acceptance in the target market (Guiltinan, 1999). An effective product launch 
is a critical driver of a company’s performance (Di Benedetto, 1999), but also one of the 
most complicated marketing procedures in existence (Amsbaugh and Pitta, 2006). NPL 
represents a more specific view on the market entry of a new product compared to the 
broader concept of commercialization (cf. Aarikka-Stenroos et al., 2014). 
The pharmaceutical industry places a heavy emphasis on research and 
development (R&D), delivering the highest ratio of R&D investment to net sales 
compared with other industrial sectors (European Federation of Pharmaceutical 
Industries and Associations, 2014a). Thus, it has a vital reliance on NPL success 
(Achilladelis and Antonakis, 2001; Corstjens et al., 2005; Feng and Gonsalves, 2010; 
Fraenkel, 2011). In this changing business environment, pharmaceutical companies aim 
to launch new drugs onto the market as quickly as possible (DiMasi, 2002; Scypinski, 
2009; Feng and Gonsalves, 2010), looking to achieve maximum market penetration and 
revenue in a limited timeframe before patent protection ends and generic competition 
begins. Moreover, the pharmaceutical industry has faced and continues to face a huge 
increase in the cost of developing new drugs while the number of approved drugs has 
declined (DiMasi et al., 2003; Terblanche, 2008; Dubey and Dubey, 2010; Kaitin and 
DiMasi, 2011; Pammolli et al., 2011). Only two out of ten marketed drugs produce 
revenues that match or exceed their average R&D costs before losing patent protection 
(Vernon et al., 2010), which typically lasts for 20 years (Terblanche, 2008). The 
successful launch of a new drug will pave the way for a pharmaceutical company’s 
performance, which then enables R&D for new products in the future (Terblanche, 
2008). Under these circumstances, it is important to elucidate pharmaceutical NPLs and 
find new ways to manage this increasingly challenging and complex activity. 
 The launch phase is the last but also the most critical, expensive, and riskiest 
phase of the new product development process (Di Benedetto, 1999; Chen et al., 2007; 
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Chiesa and Frattini, 2011). While companies commit enormous amounts of time, 
financial, and managerial resources, the average failure rate of NPLs has been as high as 
40% in new consumer and industrial products (Hultink et al., 2000), and more than 60% 
in high-tech industries (Goldenberg et al., 2001; cf. Cierpicki et al., 2000). The average 
failure rate of NPLs has still remained as high as 40-50% (Chiesa and Frattini, 2011). 
Thus, both academics and practitioners have a substantial interest in seeking the most 
relevant antecedents for successful NPLs.  
NPL has been and still is relatively under-researched and discussed in the 
academic literature (Di Benedetto, 1999; Guiltinan, 1999; Garrido-Rubio and Polo-
Redondo, 2005; Fraenkel, 2008; Chiesa and Frattini, 2011). The prevailing NPL 
research in general business literature has mainly concentrated on product advantage 
(e.g. Henard and Szymanski, 2001; Szymanski et al., 2007; Evanschitzky et al., 2012), 
and strategic and tactical launch activities and their links to success (e.g. Hultink et al., 
1997 and 2000; Di Benedetto, 1999; Guiltinan, 1999; Hultink and Robben, 1999). The 
studies of companies’ strategic orientations have emphasized a general focus on 
customers and competitors predicting new product performance through the widely 
studied concept of market orientation (e.g. Cano et al., 2004; Kirca et al., 2005).  
Although there is a vital need for successful product launches in the 
pharmaceutical industry, the literature review reveals a scarcity of NPL-related research 
in this specific industry setting. The marketing literature on pharmaceuticals has mainly 
focused on the order of market entry and the marketing mix, including the 4Ps, i.e. 
product, price, place and promotion, related topics (Stros and Lee, 2014). More 
specifically, the mainstream of pharmaceutical NPL-related literature emphasizes 
product superiority compared to that of competitors (Becker and Lillemark, 2006; 
Terblanche, 2008) and suggests that new drugs are commercialized through careful 
strategic decisions (Trim and Pan, 2005; Amsbaugh and Pitta, 2006; Rod et al., 2007; 
Stros et al., 2009) and supported by tactical marketing mix activities (Amsbaugh and 
Pitta, 2006; Rod et al., 2007; Stros et al., 2009; Stros and Lee, 2014) and sales force 
management (Ruzicic and Danner, 2007; Fraenkel, 2011).  
Only a limited number of studies have focused on the relational aspects that 
emphasize the importance of customer relationships in pharmaceutical NPLs, although 
relationship marketing has been one of the dominant paradigms within industrial 
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marketing research (e.g. Möller and Halinen, 2000) and is a common business practice 
in pharmaceutical sales (Scharitzer and Kollarits, 2000; Wright and Lundstrom, 2004; 
Rod and Saunders, 2009; Clark et al., 2011). The importance of the relationship 
approach has been identified in the pharmaceutical industry and implicitly practiced for 
quite some time. However, it has been argued that more explicit adoption and 
demonstration is needed (Rod and Saunders, 2009). As a company’s networks of 
relationships form a critical context in the business markets – which both enables and 
constrains corporate performance (Ritter et al., 2004), and because companies have 
invested heavily in managing relationships (e.g. Reinartz et al., 2004), the relationship 
approach is seen as providing a fruitful alternative determinant that complements 
current knowledge about the key antecedents of launch performance. In particular, the 
need for a customer-focused orientation that complements the traditional sales and 
marketing approach – in the pharmaceutical industry context (Burmann et al., 2011) – is 
supported by recent studies pointing out the crucial role of networks in facilitating the 
successful commercialization of radical innovations (e.g. Story et al., 2011; Aarikka-
Stenroos et al., 2014; Aarikka-Stenroos and Lehtimäki, 2014; Sandberg and Aarikka-
Stenroos, 2014) 
Overall, the pharmaceutical NPL literature is highly fragmented and focuses on 
a narrow set of themes at once, and thus a holistic overview of key NPL success 
determinants has not been obtained. Furthermore, the scarcity of customer relationship 
aspects and how they link to NPL in the pharmaceutical industry demonstrates an 
evident need for further academic study. This thesis contributes to existing NPL 
literature by providing a holistic and comprehensive overview on the key determinants 
of NPL success in the pharmaceutical industry by emphasizing the relationship 
approach and its role and impact on launch performance.  
 
1.2 Positioning in the healthcare context 
 
The pharmaceutical industry has an essential role within the healthcare system. 
Pharmaceutical companies develop, manufacture and supply medicinal drug products 
and vaccines through distribution networks and wholesalers to pharmacies, hospital 
pharmacies, and veterinarian clinics. These pharmaceutical products are used in curing 
? 4 
and preventing diseases, have diagnostic purposes and relieve symptoms of illness in 
patients and animals. In consequence, medication provides several valuable direct and 
indirect benefits for individuals and society by lengthening the lifetime of people and 
improving their ability to work and quality of life.  
A new medicinal proprietary drug product is typically an innovation to cover a 
clearly unmet medical need. Typically, meeting this need undergoes a long and costly 
R&D process with several non-clinical and clinical studies for marketing authorization. 
In addition to these proprietary products, generic products play a significant role in 
healthcare. A generic drug consists of a patent-expired active ingredient requiring minor 
scale product development activities before marketing authorization (Prasnikar and 
Skerlj, 2006). The generic substitution and the reference price system have increased 
competition in the Finnish pharmaceutical market (Kannisto and Jormanainen, 2010) 
and lowered prices (Aalto-Setälä, 2008), thus providing savings in healthcare costs. 
Several stakeholders are needed in order to bring a new medicinal drug product 
to market. First of all, the regulatory authorities must evaluate a new drug as meeting 
the applicable requirements for efficacy, safety and quality. After that, they grant the 
marketing authorization for a drug. The national pricing authorities confirm or reject 
reimbursement and set a reasonable wholesale price for a new medicinal product 
according to the national policies and regulations of a nation state. However, in the 
Finnish healthcare context, tax-based health insurance is only one part of the multi-
channel funding model. Hospital medicines are procured through competitive bidding 
by hospital districts. 
Following marketing authorization, a pharmaceutical company can place a new 
drug on the market and start promotional activities. The laws and regulations 
concerning pharmaceutical marketing vary from country to country. According to 
Finnish law, the sales and marketing of prescription medicines can only be targeted at 
healthcare professionals who are entitled to prescribe or dispense medicines and need 
pharmaceutical information in their work. These professionals include physicians, 
dentists, veterinarians, and pharmacists. Only over-the-counter medicines, which are 
available without prescription and used in self-care, may be marketed to consumers. 
Since pharmaceutical companies have commercial interests in their operations in the 
healthcare environment, the ethical considerations have been taken into account by 
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controlling pharmaceutical product promotions and by establishing the voluntary self-
regulation of the pharmaceutical industry (e.g. Pharma Industry Finland, 2014a).  
As presented above, the common features and challenges faced in the 
pharmaceutical industry are global, although each country’s healthcare system is 
unique. Hence, this thesis focuses on a country and market environment where there are 
separate parties for decision-making (i.e., physician), paying for (i.e., national health 
insurance or insurance company), and end using (i.e., patient) with respect to a new 
drug. This specific characteristic of the pharmaceutical industry exemplifies the 
business-to-business (B2B) industrial marketing setting that focuses on exchange 
between buyers (i.e. physicians) and sellers (i.e. a pharmaceutical company) (Dwyer et 
al., 1987; Clark et al., 2011). In addition to this common perspective on customers, 
customership can be seen as a wider concept of different stakeholders in the present-day 
pharmaceutical industry setting. In addition to physicians, stakeholders can include 
pricing authorities, budget holders, formulary decision-makers, advocacy groups and 
nurses, to mention a few examples. However, this thesis considers physicians as 
customers and focuses on the relationship of physicians to the pharmaceutical industry, 
but aims to extend contributions to other relevant stakeholders when applicable. 
As physicians have a key role in decision-making that is related to the drug 
treatments of patients, they face relationship-marketing activities, in which 
pharmaceutical company representatives meet physicians with the intent of establishing 
and maintaining customer relationships (Wright and Lundstrom, 2004; Clark et al., 
2011). This physician-pharmaceutical industry relationship has faced plenty of criticism 
during the last decade because it seemingly has a contradiction at its core: the 
relationship between a physicians’ autonomy and the commercial interests of the 
pharmaceutical companies (Abbasi and Smith, 2003; Moynihan, 2003a; Brennan et al., 
2006; Angell, 2009). Consequently, several studies have attempted to disentangle and 
increase transparency between physicians and the pharmaceutical industry (Moynihan, 
2003b; Stoessel, 2008; Krumholz, 2009; Robertson et al., 2009; Jack, 2011; European 
Federation of Pharmaceutical Industries and Associations, 2014b; World Medical 
Association, 2014). 
 
 
?
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1.3 Structure of the thesis 
 
This thesis builds on four original publications that examine the determinants of 
NPL success in the Finnish pharmaceutical industry. The examination is conducted 
from different perspectives and with different research methods. More specifically, 
emphasis is placed on the role and impact of determinants of NPL success on launch 
performance. The original publications are presented at the end of this thesis. 
The structure of this thesis is organized as follows. The thesis starts with a 
discussion of the extant NPL literature relevant to the research phenomenon from both 
the general business and the pharmaceutical perspectives. The comprehensive overview 
of the NPL literature provides a theoretical framework by covering the theoretical 
approaches of the study and the key concepts it applies. Then, the methodology section 
describes and justifies the design, sampling, data collection and analyses. The key 
empirical results are summarized and discussed in the light of the study aims that focus 
on the relationship approach in NPL. The thesis concludes by highlighting its 
theoretical contributions to the existing NPL literature and its practical managerial 
implications as well as suggesting avenues for future research. 
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2 Overview of the literature on launching new products 
?
The NPL literature review presents four different theoretical approaches: 
product-centered, traditional sales and marketing, strategic orientations and relationship 
approaches. First, product-centered and traditional sales and marketing approaches are 
introduced representing a well-established ground for NPL literature. Then, strategic 
orientations approach are presented since they have received an increasing interest in 
the NPL literature during recent years, followed by the largely neglected relationship 
approach. These approaches – together with success measures and the theory of 
innovation diffusion – illustrate the main research streams in the NPL context. The 
presumptions of the approaches vary and all of them highlight certain determinants of 
success in the NPL context, but do so from different perspectives. The selected 
theoretical approaches and the key concepts form a theoretical framework for this thesis 
(Figure 1).  
Figure 1. Theoretical framework and key concepts 
?
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2.1 Product-centered approach 
 
The product-centered approach represents the NPL literature stream, which 
focuses on innovation and the concept of product advantage. The product advantage 
refers to the benefits that customers receive from a new product in relation to the 
competition already on the market (Calantone and Di Benedetto, 1988; Henard and 
Szymanski, 2001), emphasizing uniqueness, innovativeness and the superior aspects of 
the new product. Furthermore, product advantage has been seen as a critical factor 
referring to “the customer's perception of product superiority with respect to quality, 
cost-benefit ratio, or function relative to competitors” (Montoya-Weiss and Calantone, 
1994; p. 415). The product advantage, representing an innovation perspective in NPL-
related literature, underlines the fact that launch performance is principally achieved by 
providing better products for customers. Rogers (2003), in his seminal theory of 
innovation diffusion, proposed that product advantage is one of a product’s 
characteristics that is positively related to new product adoption (see chapter 2.6). 
A considerable amount of extant business studies have found a positive and 
significant link between product advantage and performance in the NPL context (e.g. 
Kleinschmidt and Cooper, 1991; Montoya-Weiss and Calantone, 1994; Gatignon and 
Xuereb, 1997; Song and Parry, 1997; Henard and Szymanski, 2001; Langerak et al., 
2004; Szymanski et al., 2007). Hence, it can be expected that product advantage 
positively influences the performance of a new product because it increases the positive 
perceptions of customers about the product – in relation to its competition, thus 
speeding up customer adoption (e.g. Rogers, 2003). On the other hand, highly 
innovative products (i.e. major or radical innovations) might influence new product 
performance in negative ways due to a fear of novelty and the resulting resistance of 
customers to adopt the product (Lee and O’Connor, 2003; McNally et al., 2010; Kuester 
et al., 2012). Although recent meta-analyses examining the relationship between 
product innovativeness and new product success show conflicting evidence on the link, 
the performance relationship has been found to be mostly positive (Henard and 
Szymanski, 2001; Szymanski et al., 2007; McNally et al., 2010; Evanschitzky et al., 
2012).  
Simultaneously, the mainstream of current pharmaceutical NPL-related 
literature emphasizes product superiority compared with that of competitors 
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(Terblanche, 2008). Especially in the research-based pharmaceutical firms, it is still the 
dominant logic that a heavy emphasis on R&D produces innovative and superior 
products that have a product advantage (Terblanche, 2008; Valverde, 2010). Thus, 
product differentiation (Yeoh, 1994) and product innovation have been identified as two 
key success factors for pharmaceutical industry (Gassmann et al., 2004; Kvesic, 2008; 
Stros et al., 2009; Dubey and Dubey, 2010; Stros and Lee, 2014).  
Product advantage can also be seen as a mediating mechanism between a 
company’s strategic orientations (see chapter 2.3) and launch performance (see chapter 
2.5). The mediating role of product advantage has previously been studied by focusing 
only on the link between market orientation and new product performance (Langerak et 
al., 2004). However, several researchers have suggested investigating further relevant 
mediators in order to understand better why certain new products are more successful 
than others (Szymanski et al., 2007; Evanschitzky et al., 2012). 
?
2.2 Traditional sales and marketing approach 
?
2.2.1 Strategic choices 
?
As comprehensively summarized by Calantone and Di Benedetto (2007), NPL 
decisions and/or activities have typically been broadly divided into two categories: 
strategic or tactical. The strategic choices are difficult or expensive to change at a later 
stage of the launch process, whereas the tactical decisions are easier to modify and 
strongly influenced by the strategic choices that have already been taken (Di Benedetto, 
1999). 
The NPL literature review indicates that strategic choices focus mainly on 
product- and market-related decisions – as presented in the classic literature on strategy 
(e.g. Ansoff, 1965). The most commonly presented strategic choices in NPL literature 
are the definition of launch objectives (Talke and Hultink, 2010a), the gathering of 
market information, such as market research, market testing and customer feedback (Di 
Benedetto, 1999; Calantone and Di Benedetto, 2007), clearly defined launch strategy 
(Hultink et al., 1997, 1998, 1999 and 2000; Hsieh et al., 2006), market segmentation for 
identifying an appropriate target market (Talke and Hultink, 2010a; Chiesa and Frattini, 
2011), product positioning for the target market (Talke and Hultink, 2010a; Chiesa and 
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Frattini, 2011), and the timing of the launch (Di Benedetto, 1999; Hultink and Robben, 
1999; Prasnikar and Skerlj, 2006; Calantone and Di Benedetto, 2007; Chiesa and 
Frattini, 2011).  
The literature review reveals a similar division between strategic choices and 
tactical decisions in the pharmaceutical industry (Trim and Pan, 2005). The NPL 
strategy model shows that product strategy (i.e. a product’s image and branding), 
market strategy (i.e. market targeting and competitor-related functions), and company 
strategy (i.e. a company’s culture, mission and NPL process) compose the key strategic 
choices for pharmaceutical companies and are influenced by product, regulatory, 
technological and geographical factors (Trim and Pan, 2005). Furthermore, the 
pharmaceutical NPL literature emphasizes strategic choices, such as product positioning 
(Harms et al., 2002; Datamonitor, 2008; Stremersch and Van Dyck, 2009), market 
segmentation (Burmann et al., 2011), market research (Bogan and Wang, 2000; 
Harmancioglu et al., 2009), market access communication strategy toward key decision-
makers in the introduction of a new drug (McGrath, 2010) as well as launch timing and 
the order of market entry (Berndt et al., 2002; Corstjens et al., 2005; Stros et al., 2009; 
Stros and Lee, 2014). Particularly in the generic pharmaceutical industry, the first 
products on the market tend to achieve a high market share, while building entry 
barriers for competitors and creating brand awareness for their products (Prasnikar and 
Skerlj, 2006).  
The links between the above presented strategic choices and new product 
success have been demonstrated in the general literature on NPL (Hultink et al., 1997, 
1998, 1999 and 2000; Hultink and Robben, 1999; Di Benedetto, 1999; Calantone and 
Di Benedetto, 2007; Talke and Hultink, 2010a). However, the corresponding links 
between strategic choices and launch performance have only rarely been studied in the 
pharmaceutical NPL context, except in simulation studies that demonstrate that the 
order of entry, marketing efforts and a product’s quality attributes positively affect 
market share (Berndt et al., 2002). 
?
2.2.2 Tactical decisions 
?
Compared to the strategic choices, which answer what, where and when 
questions, the tactical decisions represent how to execute a launch in detail (Hultink et 
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al., 1997; Guiltinan, 1999; Garrido-Rubio and Polo-Redondo, 2005). According to 
Guiltinan (1999; p. 518), “launch tactics are the decisions and activities that are 
primarily used to clarify or leverage relative advantages and to demonstrate or enhance 
compatibility to the target market”. Typically, the tactical decisions follow strategic 
choices (Di Benedetto, 1999; Calantone and Di Benedetto, 2007). Furthermore, the poor 
execution of the marketing activities is said to be a reason for high failure rates 
(Harmancioglu et al., 2009).  
Tactical decisions, or launch tactics, are classically described as the marketing 
mix, including the 4Ps, i.e. product, price, place and promotion (Kotler, 1984; Hultink 
et al., 1997, 1998, 1999 and 2000; Di Benedetto, 1999). In addition to the widely 
studied concept of the marketing mix, commonly presented tactical decisions in the 
NPL literature are a sufficient marketing budget (e.g. Narayanan et al., 2004), resources 
(e.g. Di Benedetto, 1999) and the proficient execution of the marketing plan (e.g. 
Harmancioglu et al., 2009). Moreover, selling, technical support and launch 
management are seen as tactical decisions (Di Benedetto, 1999).  
Factors related to the marketing mix are also considered tactical decisions in the 
pharmaceutical industry context (Trim and Pan, 2005; Amsbaugh and Pitta, 2006; Stros 
et al., 2009; Stros and Lee, 2014). Rod et al. (2007; p.180) have noticed a need for “a 
more systematic approach to segmentation, targeting and positioning through branding 
and the marketing mix” for optimizing pharmaceutical return-on-investment. 
Furthermore, McGrath (2010) argues that a lack of effective market access activities, 
such as advisory board meetings, health outcome toolkits, advance notification 
documents, service delivery adjustments, and payer activities, are amongst the most 
common reasons why new drugs fail to reach patients in a timely manner.  
Similarly, compared to the strategic choices, the link between tactical decisions 
and launch performance has been widely studied regarding tactical decisions as key 
NPL success factors in the general business literature (Di Benedetto, 1999; Hultink et 
al., 1997, 1998, 1999 and 2000; Calantone and Di Benedetto, 2007). However, the link 
to successful launch performance has not been specifically studied in the 
pharmaceutical NPL context, excluding a case study (Datamonitor, 2008) and a survey 
study of physicians (Pitt and Nel, 1988), which demonstrated the effectiveness of 
marketing mix activities. 
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2.2.3 Sales force management 
 
Sales force management has been defined as “analysis, planning, 
implementation and control of sales force activities including designing sales force 
strategy and structure as well as recruiting, selecting, training, supervising, 
compensating and evaluating a company’s sales people” (Kotler and Armstrong, 2009). 
The effective management of a sales force is a requirement for success in business 
markets (Avlonitis and Panagopoulos, 2010).  
In the NPL context, sales force management refers to management activities 
specific to sales force operations during the launch phase of a new product (cf. 
Fraenkel, 2011). This includes sales force management-related strategic elements, 
which need to be considered in NPL, such as the composition of the sales force and its 
correct size, as well as adequate effort and commitment to a new product, control 
issues, an incentive system, and internal marketing and training with regard to the 
launched product (Cooper, 1998; Di Benedetto, 1999; Hultink and Atuahene-Gima, 
2000; Fraenkel, 2011). 
The traditional role of sales is changing “from a function to a process; from an 
isolated activity to an integrated one; and is becoming strategic rather than operational” 
(Storbacka et al., 2009; p. 890). The strategic role of sales is typically rooted in the 
relationship approach that can be regarded as aiming at simultaneously making sales 
and developing long-term relationships with major customers (e.g. McDonald et al., 
1997; Srivastava et al., 1999; Weitz and Bradford, 1999; Ingram, 2004; Mantrala et al., 
2008; Geiger and Guenzi, 2009; Storbacka et al., 2009; Avlonitis and Panagopoulos, 
2010; Davies et al., 2010). In practice, the new role of sales is demonstrated through 
concepts such as relationship selling (e.g. Crosby et al., 1990; Frankwick et al., 2001), 
consultative selling (Liu and Leach, 2001), or value-based selling (e.g. Terho et al., 
2012; Töytäri et al., 2011) all of which share the idea of value co-creation while 
interacting with the customer, hence emphasizing a relational sales approach (Vargo 
and Lusch, 2004; Grönroos, 2008; Grönroos and Helle, 2010). In summary, the 
prevailing conceptualizations concerning sales put an emphasis on building and 
maintaining customer relationships rather than merely optimizing a series of separate 
transactions.  
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Several studies show that sales represent a company’s key frontline activity in its 
customer interface and that this has a major influence on the company’s performance 
(Baldauf and Cravens, 1999; Baldauf et al., 2001; Avlonitis and Panagopoulos, 2010). 
Furthermore, plenty of studies in the NPL context have suggested that the sales force is 
a critical contributory factor to new product success (Cooper, 1998; Di Benedetto, 1999; 
Hultink and Atuahene-Gima, 2000; Fraenkel, 2011). Most importantly, the critical role 
of sales force management as a key marketing decision area for business performance 
(Stremersch and Van Dyck, 2009) and in the pharmaceutical NPL context has been 
demonstrated (Fraenkel, 2011).  
Sales representatives’ personal selling (or detailing) has traditionally been seen 
as one of the most important aspects in the selling and marketing of a new product in 
the pharmaceutical industry (e.g. Pitt and Nel, 1988; Bogan and Wang, 2000; 
Tengilimoglu et al., 2004; Stros et al., 2009; Clark et al., 2011; Fraenkel, 2011), but is 
also considered the most expensive pharmaceutical marketing activity (Black, 2005). 
The aim of personal selling is to inform physicians about the properties of a product 
with the expectation of influencing a physician’s prescription behavior (e.g. Gönül et 
al., 2001; Mizik and Jacobson, 2004; Black, 2005). This traditional sales force operation 
has faced several challenges, such as pressures on cost savings, the issue of access to 
physicians, and tightening regulations on promotion (Rod et al., 2007; Terblanche, 
2008; Fraenkel, 2011), thus improvements in sales force effectiveness and NPL are 
needed (Gönül et al., 2001; Terblanche, 2008; Fraenkel, 2011). Fraenkel’s (2011) study 
of the key success factors for sales force readiness during NPL in the Swedish 
pharmaceutical industry demonstrated that the strategic elements related to a sales force, 
such as adequate effort and commitment toward a new product, control issues, an 
incentive system, as well as internal marketing and training, need to be considered 
during a pharmaceutical NPL.  
In addition to the direct effect on the success of a launch, sales force 
management can also be seen as a mediating factor between a company’s organizational 
culture and launch performance. As a sales force plays an important role in executing 
marketing strategies (Cross et al., 2001), sales force management can be assumed to be 
a key activity through which a relationship-oriented culture is transformed into 
performance in the NPL context. Consequently, when a company has a strong desire to 
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establish, maintain, and leverage customer relationships, its relationship-focused 
activities should play a key role in sales force management and on frontline levels in the 
organization in order to accomplish launch performance. The company’s relationship 
orientation may direct the organization’s attitude toward adopting a sales force 
management that has a strong relational perspective (cf. Jayachandran et al., 2005).  
 
2.3 Strategic orientations approach  
 
During recent years, academic business scholars have devoted increasing 
interest to the strategic orientations of companies in their efforts to find determinants for 
NPL success (Gatignon and Xuereb, 1997; Talke and Hultink, 2010a; Mu and Di 
Benedetto, 2011). A company’s strategic orientations refer to the “dimension of 
organizational culture that provides the organization’s values and priorities in 
interactions with its marketplace – both customers and competitors – and influences 
more specific strategies and tactics” (Noble et al., 2002, p. 27). Hakala (2011) has 
defined orientation as an organizational culture comprising values and behavioral norms 
directing and influencing managerial decisions and the activities of a company as well 
as ways of working in the organization. Talke and Hultink (2010a) examined the same 
phenomenon by employing the term ‘corporate mindset,’ which was defined as “a 
firm’s general posture toward corporate behavior and performance” (p. 220).  
This organizational culture perspective on the strategic orientations of 
companies represents the deeply embedded values and beliefs that establish the norms 
for appropriate behavior (Deshpandé et al., 1993) and drive the choice of means to 
accomplish the desired outcomes (Moorman, 1995; cf. Day, 2000), which can have an 
effect on a company’s performance (Zhou et al., 2005). Although the concepts of the 
strategic orientations and organizational culture of companies are closely intertwined, 
the strategic orientations may act as “guiding principles that influence a firm’s 
marketing and strategy-making activities” (Noble et al., 2002, p. 25). Strategic 
orientations are company-specific and complex capabilities that can lead to competitive 
advantages (Day, 1994; Hunt and Morgan, 1995).  
Although a basis for the role of strategic orientations in NPL has been 
established (Talke and Hultink, 2010a), numerous gaps still exist regarding the role and 
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relative impact of different types of orientations and the mechanisms by which they 
affect launch performance, especially in the B2B context. While market orientation (see 
Chapter 2.3.1) has dominated the research concerning strategic orientations in the NPL 
context, “several alternative strategic orientations can be considered at the same level of 
abstraction as market orientation” (Noble et al., 2002; p. 29). Interestingly, the single 
orientation research approach has been considered inadequate (e.g. Noble et al., 2002; 
Grinstein, 2008a) and scholars have argued that combining alternative orientations 
enables companies to perform better (Grinstein, 2008a). In fact, the literature review 
reveals that multi-orientation studies in the NPL context remain scarce except for Mu 
and Di Benedetto (2011) who examined market, technology, entrepreneurial and 
networking orientations in new product commercialization. However, the networking 
orientation was seen as seeking intercompany network partners in order to support 
superior product development (Mu and Di Benedetto, 2011) and excluded customer 
relationship aspects.  
In order to compose a comprehensive understanding of the role of different 
strategic orientations affecting launch performance, this literature review focuses on 
three alternative strategic orientations: market orientation, product orientation and 
relationship orientation, which represent different complementary aspects affecting 
NPL. 
 
2.3.1 Market orientation 
 
Market orientation is one of the most studied topics in the extant marketing 
literature and it refers to the implementation of the marketing concept (Lafferty and 
Hult, 2001; Cano et al., 2004; Kirca et al., 2005; van Raaij and Stoelhorst, 2008). 
Market orientation studies can be divided into either behavioral or cultural 
conceptualizations. Kohli and Jaworski (1990; p. 3) define market orientation as “the 
organization wide generation, dissemination, and responsiveness to market intelligence” 
emphasizing its behavioral perspective. On the other hand, Narver and Slater’s (1990; p. 
20) definition of market orientation as “the organization culture…that most effectively 
and efficiently creates the necessary behaviors for the creation of superior value for 
buyers” highlights the cultural perspective. However, both perspectives share the 
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common idea that the ultimate objective of a market-oriented company is to create 
superior value for the customer (Kohli and Jaworski, 1990; Narver and Slater, 1990).  
In addition to these customer-centric definitions of market orientation, several 
studies have acknowledged the competitor component of market orientation (e.g. 
Narver and Slater, 1990; Gatignon and Xuereb, 1997; Langerak et al., 2004; Gotteland 
and Haon, 2010). Narver and Slater (1990; pp. 21-22) define competitor orientation as 
“a seller understands the short-term strengths and weaknesses and long-term capabilities 
and strategies of both the key current and the key potential competitors” whereas 
Gatignon and Xuereb (1997, p. 78) define it as ‘‘the ability and the will to identify, 
analyze, and respond to competitors’ actions’. In addition to the customer and 
competitor focus, the concept of market orientation is commonly complemented by a 
third component that varies from one study to another, usually this third component is 
inter-functional coordination (e.g. Narver and Slater, 1990; Langerak et al., 2004). 
The majority of market orientation studies have confirmed the significant 
positive relationship between market orientation and business performance in general 
(e.g, Jaworski and Kohli, 1993; Slater and Narver, 1994; Kirca et al., 2005; Shoham et 
al., 2005; van Raaij and Stoelhorst, 2008; Akomea and Yeboah, 2011). The wealth of 
these studies acknowledges the significant role and importance of market orientation in 
business literature. However, non-significant or mixed direct relationships have also 
been reported between market orientation and general business performance (Langerak, 
2003).  
Market orientation has been a predominant strategic orientation perspective in 
NPL research. The majority of studies have indicated a positive direct relationship 
between market orientation and new product success (e.g. Slater and Narver, 1994; 
Atuahene-Gima, 1995; Pelham and Wilson, 1996; Appiah-Adu, 1997; Appiah-Adu and 
Singh, 1998; Baker and Sinkula, 1999; Subramanian and Gopalakrishna, 2001; Matsuno 
et al., 2002; Kirca et al., 2005; Ledwith and O’Dwyer, 2009; Carbonell and Escudero, 
2010; Mu and Di Benedetto, 2011; Wong and Tong, 2013). The rationale for this 
positive relationship lies in the way that market-oriented companies invest in 
understanding their customers and competitors. This helps them to satisfy customer 
needs and attract new customers, eventually leading to better financial performance 
(Homburg and Pflesser, 2000). However, non-significant relationships between market 
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orientation and new product success have also been reported (e.g. Greenley, 1995; 
Appiah-Adu and Ranchhod, 1998; Langerak, 2003; Langerak et al., 2004; Paladino, 
2007).   
Although a rich body of literature on market orientation and new product 
success exists, most of the existing studies have ignored the role of the mediating 
mechanisms through which market orientation affects launch performance (Mu and Di 
Benedetto, 2011; cf. Shoham et al., 2005). The few exceptions have demonstrated the 
idea that product advantage (Langerak et al., 2004), new product creativity (Im and 
Workman, 2004), new product development proficiency and product meaningfulness 
(Hong et al., 2013) are the key mediating variables explaining the link between market 
orientation and launch performance. These mediating effects are logical since market 
orientation enables companies to gain deep customer and competitor insights, thereby 
helping them to innovate and develop superior products (Langerak et al., 2004; 
Grinstein, 2008b) and leading to higher customer acceptance and better financial 
performance for the company. In addition, the role of organizational learning has been 
found to mediate the link between a combination of strategic orientations and the 
commercialization performance of a new product (Mu and Di Benedetto, 2011). 
However, the exact mechanisms by which market orientation affects launch 
performance remain obscure, which means there is a need to find more complete 
explanations. 
While numerous studies have shown the importance of market orientation in 
NPL, the heavy emphasis on market orientation can also be seen as a limitation. The 
predictive power of market orientation has been argued to be still an open issue 
(Langerak, 2003). However, many scholars also state that a solely market-oriented view 
can be risky for company performance because an overemphasis on customers might 
constitute a barrier to the commercializing of new technology and result in a decrease in 
a company’s innovative competence (Christensen and Bower, 1996; Zhou et al., 2005), 
and therefore lead to only marginally new products (e.g. Tauber, 1974; Bennett and 
Cooper, 1981; Gatignon and Xuereb, 1997; Voss and Voss, 2000; Langerak et al., 2004; 
Zhou et al., 2005). Similarly, the extant research on a company’s market orientation in 
the NPL context to date neglects almost completely the role of customer relationships, 
although the importance of business relationships and relationship marketing for 
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business performance have been widely noted (e.g. Grönroos, 2004; Morgan and Hunt, 
1994; Möller and Halinen, 2000). Due to this criticism, this study broadens the focus on 
the two complementary strategic orientations in order to overcome the limitations 
addressed above and to better understand the role of alternative strategic orientations 
regarding launch performance as a whole.  
 
2.3.2 Product orientation 
 
The concept of product orientation offers a contrasting perspective to market 
orientation’s external focus on customers and competitors. Product orientation refers to 
a company’s product-centered organizational culture in which the development and 
commercialization of new and innovative products are considered key factors for 
success (Schmidt, 1995; Gatignon and Xuereb, 1997; Narver et al., 2004; Zhou et al., 
2005). The product orientation can be regarded as the result of a technology and 
product-oriented management that focuses “energy on making good products and 
improving them over time” (Kotler, 1984, p. 17; Gatignon and Xuereb, 1997).  
The concept of product orientation has been discussed in the marketing 
literature, although it has only received limited empirical attention (cf. Voss and Voss, 
2000). This applies in the NPL context as well, although the importance of new product 
development (e.g. Krishnan and Ulrich, 2001) and positive relationships between 
product innovativeness and/or product advantage with new product success have been 
widely reported (e.g. Kleinschmidt and Cooper, 1991; Hurley and Hult, 1998; Henard 
and Szymanski, 2001; Szymanski et al., 2007; Evanschitzky et al., 2012).  
Prior research has also noted the value of product orientation for new product 
development (e.g. Song and Parry, 1997) but only a few studies have identified the 
relationship between product orientation and new product success (Narver et al., 2004; 
Mu and Di Benedetto, 2011). This implies that product orientation can also play a 
positive role in launch performance since a company’s focus on R&D and desire to 
develop superior products for a market can lead to product advantage (Zhou et al., 
2005), and thereby improve customer adoption and new product performance 
(Montoya-Weiss and Calantone, 1994; Henard and Szymanski, 2001). 
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Furthermore, similarly compared to market orientation, the existing studies have 
ignored the role of mediating mechanisms – through which product orientation affects 
launch performance (cf. Mu and Di Benedetto, 2011). As product orientation is 
positively associated with innovations, especially with technology-based innovations 
(Zhou et al., 2005), and product advantage has been confirmed as the most important 
success factor in new product performance (Henard and Szymanski, 2001; Szymanski et 
al., 2007; Evanschitzky et al., 2012), product advantage can be assumed to mediate the 
link between product orientation and performance.  
Although the concept of product orientation has been generally criticized for 
ignoring key customer and competitor perspectives in innovation, focusing on a product 
has the potential to lead to better performance compared to having a customer focus, at 
least in particular contexts (Voss and Voss, 2000). In addition, Cooper (1984) has stated 
that an innovation’s commercial performance is highly linked to a strong R&D 
orientation that can stem from inside the company. Importantly, as several authors have 
suggested that a highly market-oriented culture can lead to imitations and to only 
marginally new products (cf. Bennett and Cooper, 1981; Langerak et al., 2004), the 
assessment of a company’s product and market orientation can create novel knowledge 
regarding the role of a company’s internal versus external focus on performance in the 
NPL context. For these reasons, this study complements market orientation with the 
product-oriented perspective by providing an alternative, significantly different internal 
company view on NPL. Arguably, the simultaneous assessment of a company’s market 
and product orientation with respect to performance can create novel knowledge about 
the role of a company’s internal versus external focus on success in the NPL context. 
 
2.3.3 Relationship orientation 
 
The concept of relationship orientation, or the corresponding term: relationship 
marketing orientation, refers to an organizational culture that considers customer 
relationships as a key driver of organizational performance, pervading all parts of an 
organization through a common mindset, shared values, and norms (Day, 2000; 
Jayachandran et al., 2005). The concept of relationship orientation has been defined 
“the extent to which a company engages in developing long-term relationships with its 
? 20 
customers” (Sin et al., 2005a, p. 43), and the “desire to engage in a strong relationship 
with a current or potential partner to conduct a specific exchange” (Palmatier et al., 
2008, p. 175). Hence, relationship orientation, including dimensions such as bonding, 
empathy, reciprocity, trust, shared value, and communication (Yau et al, 2000; Sin et 
al., 2005b), represents a company’s organizational culture, underlining the 
implementation of relationship marketing.  
Whereas the widely examined concept of market orientation highlights customer 
needs and competitors at a general level (e.g. Lafferty and Hult, 2001; Cano et al., 2004; 
Kirca et al., 2005), and product orientation highlights product-related aspects, a 
relationship orientation provides a more specific customer perspective by emphasizing 
the importance of establishing and leveraging customer relationships in business (Day, 
2000). Thus, relationship orientation can be regarded as one of the strategic orientations 
of a company (cf. Day, 2000) providing a relational perspective on the buyer-seller 
dyad (Dwyer et al., 1987; Palmatier et al., 2008). 
Despite being the key element determining the effectiveness of relationship 
marketing (Palmatier et al., 2008), the literature review reveals a scarcity of empirical 
research examining the link between relationship orientation and business performance 
in general, especially in the NPL context. Although a few earlier studies have identified 
relationship orientation as a factor in maintaining a company’s competitive advantage 
and business performance (Yau et al., 2000; Sin et al., 2002; Tse et al., 2004; Sin et al., 
2005a; Winklhofer et al., 2006; Palmatier et al., 2008; Alrubaiee and Al-Nazer, 2010; 
Stewart et al., 2012; Salojärvi et al., 2015), empirical studies on relationship orientation 
in the NPL context have not been published.  
Due to the widely noted importance of the relationship marketing concept in 
business performance (e.g. Morgan and Hunt, 1994; Grönroos, 1997; Berry, 2002; 
Palmatier et al., 2006), the concept of relationship orientation can be expected to play a 
significant role in explaining launch performance. Due to the fact that relationship 
orientation considers customer relationships a key driver of organizational performance 
(e.g. Day, 2000; Jayachandran et al., 2005), it can be assumed to have a substantial 
impact on launch performance based on the theory of innovation diffusion (see chapter 
2.6). More specifically, a company’s relationship orientation might enable the faster and 
more extensive diffusion of innovation (e.g. D’Arcy, 2009; Iyengar et al., 2011) through 
? 21 
the improving of customer participation and the establishing of stronger relationships 
with customers when launching new products (e.g. Fang, 2008), resulting in lowered 
innovation diffusion barriers (cf. Talke and Hultink, 2010b) as well as an increase in 
loyal customer relationships and higher sales (e.g. Palmatier et al., 2008). Similarly to 
other strategic orientations, the mechanisms through which relationship orientation 
affects launch performance remain unstudied.  
In addition to the seller company’s perspective, relationship orientation can also 
be seen from a buyer’s perspective. Palmatier et al. (2008) have identified a buyer’s 
relationship orientation as a factor that determines the effectiveness of a seller’s 
relationship marketing in the B2B context. However, earlier studies on the attitudes of 
physicians toward the pharmaceutical industry had a limited focus – mainly on sales 
representatives and gifts in the 1980s and 1990s (e.g. Manchanda and Honka, 2005). 
Doran et al. (2006) deepened knowledge about the forms of interaction and ethical 
concerns in the physician-pharmaceutical industry relationship among specialists, but 
urged further qualitative studies on this relationship. A more thorough understanding of 
this relationship and its antecedents is essential if we are to achieve a mutually 
meaningful and beneficial relationship (Manchanda and Honka, 2005; Royal College of 
Physicians, 2009; Tiner, 2009), and to find an optimal win-win situation for both 
parties. This would decrease unnecessary and time-consuming sales and marketing 
activities when limited resources are available and it would help to target marketing 
activities toward the primary work needs of physicians.  
In summary, since the extant strategic orientation literature has neglected the 
specific role of customer relationships, the concept of relationship orientation would 
complement the two company strategic orientations discussed above, by aiming to 
provide novel knowledge not only about the role of customer relationships but also on 
other relevant stakeholder relationships in the NPL context (cf. Talke and Hultink, 
2010b). Furthermore, the examination of the concept of relationship orientation from a 
buyer’s perspective would bring a novel approach to research into the complex 
physician-pharmaceutical industry relationship. 
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2.4 Relationship approach 
 
2.4.1 Relationship marketing activities 
 
The traditional sales and marketing approach has faced a ‘paradigm shift’ from 
transactional marketing toward the relationship marketing concept that focuses on the 
establishment and maintaining of relationships with customers (e.g. Grönroos, 1994 and 
1997; Morgan and Hunt 1994; Gummesson, 1998; Storbacka et al., 2009). The concept 
of relationship marketing has been one of the dominant paradigms and key research 
streams in industrial marketing literature and research (e.g. Morgan and Hunt, 1994; 
Grönroos, 1997; Möller and Halinen, 2000; Coviello et al., 2002; Palmatier et al., 2006; 
Wong et al., 2010). According to Morgan and Hunt (1994, p. 22), “[r]elationship 
marketing refers to all marketing activities directed toward establishing, developing, 
and maintaining successful relational exchanges”. Relationship marketing can also be 
perceived from a more philosophical perspective that emphasizes the primary 
importance of relationships in business (e.g. Gummesson, 1998; Grönroos, 2008). 
The overall importance of the relationship marketing concept in business 
performance has been widely noted (e.g. Morgan and Hunt, 1994; Grönroos, 1997; 
Berry, 2002; Palmatier et al., 2006). In fact, relationship marketing has been found to be 
a central predictor of business performance because it generates stronger customer 
relationships that enhance sales growth, market share and profits (e.g. Crosby et al., 
1990; Morgan and Hunt, 1994; De Wulf et al., 2001; Palmatier et al., 2008). Trust, 
commitment, and gratitude are the key elements behind the effectiveness of relationship 
marketing on performance (Morgan and Hunt, 1994; Palmatier et al., 2006; Palmatier et 
al., 2009). On the other hand, relationship marketing has also been criticized for being 
ineffective or even counterproductive in certain circumstances (Cao and Gruca, 2005). 
Ineffective relationship management can be an important contributor to new product 
failure in technology-based industrial markets (Athaide and Klink, 2009; Athaide and 
Zhang, 2011). 
Despite the apparent importance of adopting a relational approach to business, 
empirical evidence on the effectiveness of relationship marketing activities in the NPL 
context as well as studies concerning how companies actually employ relationships in 
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the NPL setting remain fragmented and scarce. The existing studies on the topic 
indicate that relationship-focused activities play a central role in attaining a better 
launch performance. The recent conceptual and qualitative studies demonstrate the 
importance of networks in the commercialization of radical innovations (Story et al., 
2011; Aarikka-Stenroos et al., 2014; Aarikka-Stenroos and Lehtimäki, 2014; Sandberg 
and Aarikka-Stenroos, 2014). The current research has also found evidence that close 
customer interaction during new product development (e.g. Gruner and Homburg, 2000; 
Von Hippel, 2001; Fang, 2008), as well as the early identification and involvement of 
opinion leaders (e.g. van Eck et al., 2011) are factors for enhancing the success of new 
products. Moreover, the active leveraging of a company’s present customer 
relationships through key account management practices (e.g. McDonald et al., 1997) 
have been shown to be crucial for the successful launch of a new product since existing 
customers also represent a major group of adopters (see chapter 2.6). Furthermore, 
customer-related conflict management has an important role in relationship building 
(e.g. Weitz and Bradford, 1999; Naoui and Zaiem, 2010) and in efficient relationship 
marketing (e.g. Palmatier et al., 2006). 
Particularly in the pharmaceutical industry setting, the instigating of pro-active 
early market activities aimed at building product awareness among key stakeholders 
before launch – by involving potential early adopters, for example, through conferences, 
or providing high-quality training for customers – has been considered important for 
NPL success (Sandberg, 2002; Black, 2005; Rod and Saunders, 2009). Studies have 
further stressed the importance of the selection of opinion leaders (see chapter 2.6) as a 
key marketing decision area for business performance and patient welfare (Stremersch 
and Van Dyck, 2009). In addition, the need for market access-focused activities aimed 
at stakeholders and gatekeepers (e.g. decision-makers), who can have a major impact on 
the adoption of new products, for example, through advisory board meetings, has been 
noted (McGrath, 2010). Nevertheless, empirical studies have adopted a somewhat 
narrow view when studying the leveraging of relationships in the pharmaceutical NPL 
context. 
Furthermore, launch performance depends on a broad set of actors and not only 
customers, highlighting the need to adopt a broad perspective on relationships in the 
NPL context (cf. Talke and Hultink, 2010b). In other words, it is relevant to take into 
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account a broader set of stakeholder relationships that affect the adoption of a launched 
product rather than solely limiting activities to customer-directed efforts for building 
close relationships. Accordingly, in this thesis, relationship marketing activities refer to 
a company’s activities that are aimed at establishing, leveraging and capitalizing on 
relationships with its customers and key stakeholders for the successful launch of a new 
product. As relationship marketing activities focus on improving both the participation 
of customers and stakeholders and the establishment of customer and stakeholder 
relationships (e.g. Fang, 2008), they can also result in lowered innovation diffusion 
barriers (Talke and Hultink, 2010b; see chapter 2.6). Hence, a company’s efforts in 
systematic relationship marketing activities signifies a key means for putting 
relationship marketing philosophy into practice, but also forms a theoretical link to 
improved customer acceptance in the NPL context. Thus, the examination of the linkage 
between relationship marketing activities and launch performance can provide novel 
insights into the effective implementation of the relationship approach when launching 
new products.  
In addition to the direct link between relationship marketing activities and a 
successful NPL, these activities can be assumed to mediate the putting of the abstract 
relationship-oriented organizational culture into practice through concrete frontline 
activities, thus leading to better customer performance (cf. Stewart et al., 2012). In fact, 
a company’s relationship orientation may direct its organization’s attitude toward 
adopting relationship marketing activities that comprise a strong relational perspective 
(cf. Jayachandran et al., 2005). In practice, examining the role of relationship marketing 
activities in the link between relationship orientation and launch performance can 
provide novel insight into the implementation of relationship marketing philosophy, 
particularly when launching new products. 
 
2.4.2 Market-based assets 
 
Market-based assets represent another key concept in the relationship approach 
to NPL. The concept of market-based assets is rooted in the theory of the resource-
based view, emphasizing the achievement of sustainable competitive advantage through 
unique resources that are challenging to imitate (Wernerfelt, 1984; Srivastava et al., 
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1998). These strategically valuable resources include organizational assets (Srivastava 
et al., 2011), which can be divided into tangible (e.g. prime location) and intangible 
assets (e.g. strong brand) or capabilities (e.g. efficient processes) (Collis and 
Montgomery, 2008).  
The largely intangible market-based assets refer to “a reservoir of cash flow that 
has accumulated from marketing activities but has not yet translated into revenue” (Rust 
et al., 2004, p. 78). The market-based assets can be further categorized as a company’s 
internal and knowledge focused intellectual assets as well as its externally focused 
relational assets (Srivastava et al., 1998 and 2001). The relational market-based assets, 
such as brand equity and customer equity (Rust et al., 2004), and brand awareness, 
brand preference and built customer base (Grewal et al., 2009) are the “outcomes of the 
relationship between a firm and key external stakeholders, including distributors, 
retailers, end customers, other strategic partners, community groups, and even 
governmental agencies” (Srivastava et al., 1998; p. 5). In other words, relational 
market-based assets demonstrate that “stronger customer relationships are created when 
the firm uses knowledge about buyer needs and preferences to build long-term 
relational bonds between external entities and the firm” (Srivastava et al., 1998; p. 5). 
Since the concept of market-based assets underlines a company’s investments to 
customers, they are understood as the accumulated market and customer-related assets, 
such as company brand, customer base and loyalty, and the strong prior customer 
relationships of the outcome of a company’s operation in the market, (Srivastava et al., 
1998; De Wulf et al., 2001; Srivastava et al., 2001; Rust et al., 2004; Athaide and Klink, 
2009; Grewal et al., 2009; Ramaseshan et al., 2013).  
The literature on marketing indicates that if a company has appropriate 
marketing strategies and tactical action in place, they will lead to the accumulation of 
market-based assets (e.g. Rust et al., 2004; Grewal et al., 2009). Previous studies have 
demonstrated a positive link between marketing expenditure and company performance 
through the creation of market-based assets (e.g. Srivastava et al., 1998; Rust et al., 
2004; Grewal et al., 2009; Ramaswami et al., 2009). However, this specific link 
between market-based assets and improved performance has not been studied in the 
NPL context, although the market-based assets that emphasize established customer 
relationships might act as a central means for lowering customer adoption barriers to 
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innovations, therefore improving customer acceptance (Srivastava et al., 1998; 
Ramaswami et al., 2009; Talke and Hultink, 2010b) and increasing financial 
performance (Talke and Hultink, 2010b).  
In addition to the direct performance link, the concept of market-based assets 
can be seen as a mediator between a company’s strategic orientations and launch 
performance. According to the theory of innovation diffusion (see chapter 2.6), it can be 
assumed that market-based assets might mediate the effect of market orientation on 
customer acceptance by expediting product adoption among customers. Furthermore, 
the market-based assets might mediate the link between product orientation and launch 
performance since a company’s commitment to developing superior products can help 
to generate market-based assets and improve launch performance. The market-based 
assets can also be assumed to mediate the link between the relationship orientation and 
launch performance due to the proposition that a relationship orientation that 
emphasizes the importance of customer relationships enhances the opportunities of a 
company to accumulate customer relational market-based assets (Srivastava et al., 
1998), which in turn improve launch performance. 
 
2.5 Success measures 
?
The term success is relative to expectations and refers to the achievement or 
exceeding of the set milestones or goals. New product success, or even the alternative 
term of launch performance, can be perceived as the outcome of a complete new 
product development project that can be measured in terms of both short- and long-term 
dimensions (De Brentani et al., 2010). Launch performance can also be defined as “the 
ability of a new product or innovation to avoid failure in the marketplace” (Paladino, 
2007; p. 541).  
A thorough evaluation of launch performance comprises both customer 
acceptance and financial performance measures. Since the customer adoption of a new 
product is essential for improved financial performance and poor customer acceptance 
is a reason for market failure (Chiesa and Frattini, 2011), the role and impact of 
different determinants affecting launch performance should be studied from both 
customer acceptance and financial perspectives (Scharitzer and Kollarits, 2000; Berndt 
et al., 2002). Therefore, it is considered worthwhile to distinguish between these two 
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areas of launch performance. Furthermore, since this thesis involves customer- and 
relationship-focused concepts, it is logical to expect that customer acceptance represents 
a key measure in explaining how these concepts link to the improved financial 
performance of a launch.  
Customer acceptance refers to customer-related success that plays a key role in 
attaining broader financial launch targets (e.g. Griffin and Page, 1993 and 1996; 
Homburg and Pflesser, 2000). Customer satisfaction and customer acceptance are 
identified “as the most useful customer-based measures of success” at the project level 
(Griffin and Page, 1996, p. 478). Furthermore, based on the theory of innovation 
diffusion (see chapter 2.6), customer acceptance represents a key determinant for NPL 
success as the adoption of a new product by customers is necessary for improved 
financial performance (Rogers, 2003). 
Whereas customer-based success measures relate to customer acceptance, the 
measures of financial launch performance refer to the overall attainment of financial 
launch targets relating to sales, market share and profitability (e.g. Montoya-Weiss and 
Calantone, 1994; Di Benedetto, 1999; Talke and Hultink, 2010a and 2010b). These 
financial measures have been frequently employed as appropriate tools for measuring 
success in the NPL literature (e.g. Montoya-Weiss and Calantone, 1994; Di Benedetto, 
1999; Kleinschmidt et al., 2007; De Brentani et al., 2010; Talke and Hultink, 2010a and 
2010b).  
 
2.6 Innovation diffusion 
 
The seminal theory of innovation diffusion has helped scholars and practitioners 
understand and manage the market penetration of new products. More specifically, the 
term describes how an innovation spreads and is diffused throughout a market (Rogers, 
2003). This social contagion theory was developed to explain the adoption behavior of 
innovations by individuals as a function of the knowledge, attitude or behavior toward 
specific innovations that was displayed by other individuals (Rogers, 2003). Without 
the adoption of an innovation, the diffusion of the innovation will not occur, since 
“individual adopter-level adoptions are seen as building blocks of the macro-level 
phenomenon of diffusion” (Makkonen and Johnston, 2014; p. 325).  
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The innovation adoption process includes a series of steps, which an individual 
or an organization goes through in deciding whether or not to adopt a new product and 
its rate depends, in part, on product characteristics (Guiltinan, 1999). The diffusion 
theory supposes that several factors influence new product adoption by promoting or 
delaying the diffusion process, including perceived innovation characteristics such as 
product advantage, compatibility, complexity, trialability and observability (Rogers, 
2003). The individual patterns of adoption have been classically divided into five 
categories (Table 1), which define how an innovation is adopted in the different phases 
of a product’s lifecycle along the innovation adoption curve (Figure 2) (Moore, 2002; 
Rogers, 2003).  
Table 1. Description of the adopter categories  
??????????Innovation adoption curve and the adopter categories  
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Some recent studies have focused on innovation diffusion barriers, which 
represent the challenges and obstacles faced in a new product’s commercialization 
phase, and thus diminish the diffusion of an innovation (Talke and Hultink, 2010b; 
D’Este et al., 2012; Sandberg and Aarikka-Stenroos, 2014). The restrictive mindset of 
companies, referring to their internal resistance to innovations (i.e. restrictive 
organizational culture, and fear of change or failure), and undeveloped networks have 
been recognized as key diffusion barriers to radical innovations in commercialization 
literature (Sandberg and Aarikka-Stenroos, 2014). Launch activities have to overcome 
or lower diffusion barriers that are related to customers and other relevant stakeholders 
in order to aim for a successful launch (Talke and Hultink, 2010b), especially in the 
case of radically new products (Kuester et al., 2012; Sandberg and Aarikka-Stenroos, 
2014). 
The critical role of external opinion leaders in the adoption process of new 
products has been noted both in general business (e.g. van Eck et al., 2011; Cho et al., 
2012) and pharmaceutical literature (e.g. Sandberg, 2002; Corstjens et al., 2005; 
D’Arcy, 2009; Smith, 2009). In practice, “the adoption of new ideas spreads throughout 
a population through the observed usage and endorsement of opinion leaders” (Smith, 
2009; pp. 293-294). Therefore, in this study context, the previously defined concept of 
customer acceptance (see chapter 2.5) is divided into two parts: key opinion leaders 
(KOL) and the majority of other target customers. This has been done in order to 
represent the early and mainstream market segments. KOL refers to an external medical 
expert, who is recognized and valued by colleagues, and has a significant influence on 
his/her peers. Furthermore, the opinion leaders can be classified into clinical leaders and 
market leaders based on their specific expertise in a certain therapy or disease area and 
strong clinical research experience. On the other hand, their status as leaders can be 
based on tight connections to local physician communities (Stremersch and Van Dyck, 
2009). The relatively limited number of existing studies on the efficiency of opinion 
leaders indicates that the involvement of a KOL is an important antecedent for the 
market penetration of a new drug (Sandberg, 2002; Manchanda et al., 2005; Smith, 
2009). The majority of other target customers refers to other physicians, who are 
potential prescribers of a new drug.  
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The prescribing of a new drug by physicians is one example of the innovation 
adoption process. The prescribing behavior of physicians has received wide attention in 
previous decades (Hemminki, 1975; Bradley, 1991; Mason, 2008). These studies have 
largely concentrated on gifts, samples and the frequency of the meetings of physicians 
with sales representatives (e.g. Wazana, 2000; Watkins et al., 2003; Manchanda and 
Honka, 2005; Campbell et al., 2007; Naik et al., 2009; Spurling et al., 2010). However, 
only a few of the previous studies examining the adoption of a new drug by physicians 
have utilized Rogers’s (2003) theoretical framework of innovation diffusion (Ruof et 
al., 2002; Liu et al., 2011; Zappa and Mariani, 2011; Ruiz-Conde et al., 2014), although 
the application of this seminal framework in investigating health care innovations has 
been highly recommended (Berwick, 2003; Greenhalgh et al., 2004).  
The adoption of a new drug is a complex and multi-factor process (Denig et al., 
1988; Jones et al., 2001; Buusman et al., 2007) that has been studied but mainly in 
specific disease or medicinal product settings (e.g. Bradley, 1991; Buban et al., 2001; 
Ruof et al., 2002; Buusman et al., 2007; Mason, 2008; Naik et al., 2009). The factors 
affecting the introduction of a new drug have been categorized in a number of ways 
(Hemminki, 1975; Jones et al., 2001; Groves et al., 2002; Prosser et al., 2003; Buusman 
et al., 2007; Mason, 2008). The review by Groves et al. (2002) indicates that the 
adoption of a new drug depends on attitudinal changes in individuals. Coleman et al. 
(1957) demonstrated that interaction with colleagues affected the adoption decisions of 
physicians. However, although some recent studies have focused on the attitudes of 
physicians toward innovation (Carter, 2008) and their relationships with patients 
(Mason, 2008), a physician-pharmaceutical industry relationship has not previously 
been the focal point of new drug adoption studies.  
 
2.7 Research gaps  
?
The literature on NPL is highly fragmented, focusing on a narrow set of themes 
and thus a holistic and comprehensive overview on the key determinants of NPL 
success has not yet been obtained. Despite the apparent importance of adopting a 
relationship approach in industrial marketing, the literature review revealed a scarcity of 
studies focusing on the relationship approach in both general and pharmaceutical NPL 
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contexts. Furthermore, empirical evidence concerning how companies actually employ 
relationships in the NPL setting remains limited, demonstrating an evident need for 
further academic study.  
More specifically, although a basis for considering the role of strategic 
orientations in NPL has been established, the vast majority of studies examining the 
impact of the strategic orientations of companies on NPL success have, to date, focused 
on the concept of market orientation, underlining the point of view of general customers 
and competitors but omitting customer relationships. Thus, numerous gaps still exist 
regarding the role and relative impact of alternative strategic orientations in the NPL 
context. No previous studies investigating the role and impact of a company’s strategic 
orientations on launch performance in the pharmaceutical industry setting have been 
published. 
Besides the concept of relationship orientation, which has been studied from the 
seller’s perspective, only a few studies have adopted the buyer’s perspective on 
relationship orientation. In particular, earlier studies on the attitudes of physicians 
toward the pharmaceutical industry have limited their focus mainly to the consideration 
of sales representatives, gifts, and ethical considerations. The physician-pharmaceutical 
industry relationship has not been the focal point in previous studies. Hence, a more 
thorough understanding of this relationship and its antecedents is essential for achieving 
a mutually meaningful and beneficial relationship between physicians and the 
pharmaceutical industry. 
Although a strong theoretical rationale exists for arguing that the different 
strategic orientations of companies influences the success of new products through very 
different mechanisms, the exact mechanisms through which these orientations affect 
launch performance remain largely unstudied. Furthermore, understanding a company’s 
orientation remains incomplete if it is not known through which activities its 
organizational culture is transformed into launch success.  
Although there is a vital need for successful product launches in the 
pharmaceutical industry, the mainstream of pharmaceutical marketing literature has 
mainly focused on product superiority and traditional sales and marketing activities, 
thus neglecting the relationship approach to some extent. There is a clear need to 
understand comprehensively the key determinants of NPL success and their impact on 
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launch performance by using both customer-related and financial performance 
measures. Furthermore, the diverse determinants of success have not been explicitly 
linked to the different stages of product lifecycle in the pharmaceutical NPL setting.  
The previous studies on the prescribing behaviour of physicians have 
concentrated mainly on gifts, samples and the frequency of their meetings with sales 
representatives. However, only a few studies have utilized the seminal theoretical 
framework of innovation diffusion. Furthermore, the physician-pharmaceutical industry 
relationship has not previously been the focal point of new drug adoption studies. 
Therefore, a deeper understanding of the physician-pharmaceutical industry relationship 
and knowledge about how this relationship is reflected when a physician begins to 
prescribe a new drug may provide a relevant addition to the existing research on NPL 
with respect to the pharmaceutical industry.  
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3 Aims of the study 
?
 
 
The purpose of this thesis was to obtain a holistic and comprehensive overview 
on the key determinants of NPL success in the pharmaceutical industry. In order to 
acquire this overview, the largely neglected relationship approach needs to be taken into 
account. Thus, this study wants to answer the research question: What is the role and 
impact of relationship approach in the successful launch of a new product? Specifically, 
this study examines the role of the key determinants in the pharmaceutical NPL context 
from the perspectives of both buyers and sellers, and studies their impact on launch 
performance, including both customer acceptance and financial performance measures.  
 
More specifically, the aims of the present study were to 
 
1. Examine the role and relative impact of three alternative company’s strategic 
orientations, namely market orientation, product orientation and relationship 
orientation, on launch performance (I-III) 
2. Study the attitudes of physicians toward the pharmaceutical industry that reflect 
their relationship orientation to it, and to identify the antecedents of that 
relationship orientation (IV) 
3. Examine the alternative mediating mechanisms, namely product advantage and 
market-based assets, and the key activities, namely sales force management and 
relationship marketing activities, by which a company’s strategic orientations affect 
launch performance in the NPL context (I-II) 
4. Identify and rank the most important individual determinants of NPL success that 
affect both customer acceptance and financial success measures at the different 
stages of the innovation adoption curve (III) 
5. Study the physician-pharmaceutical industry relationship and interaction in order to 
build a mutually meaningful and beneficial collaboration between physicians and 
pharmaceutical companies, and to investigate how this relationship is reflected in 
introduction of a new product (IV) 
 
A summary of the research gaps, the research questions and the study aims is presented 
in Table 2. 
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Table 2. Research gaps, research questions and study aims 
No. Research gap Research question Study aim 
 The fragmented NPL 
literature and the limited 
number of studies focusing 
on the relationship approach 
omitting links to launch 
performance  
What is the role and 
impact of the relationship 
approach in the successful 
launch of a new product?  
 
To provide a holistic and 
comprehensive overview on the key 
determinants of NPL success, 
especially focusing on the relationship 
approach  
1 The role and relative impact 
of the alternative company’s 
strategic orientations on 
launch performance 
What is the role and 
relative impact of the 
alternative strategic 
orientations of a company 
on launch performance? 
To examine the role and relative 
impact of three alternative company’s 
strategic orientations – market 
orientation, product orientation and 
relationship orientation – on launch 
performance (I-III) 
2 The buyer’s perspective on 
the relationship orientation 
with the physician-
pharmaceutical industry 
relationship as the focal point  
 
How are the attitudes of 
physicians toward the 
pharmaceutical industry 
reflected in their 
relationship orientation 
and what are the key 
antecedents of their 
relationship orientation?  
To study the attitudes of physicians 
toward the pharmaceutical industry 
and to identify the antecedents of their 
relationship orientation (IV) 
3 The theoretical mechanisms 
by which the companies’ 
strategic orientations affect 
launch performance 
How are a company’s 
abstract strategic 
orientations transformed 
into launch performance? 
 
To examine the alternative mediating 
mechanisms – product advantage and 
market-based assets –  
and the key activities – sales force 
management and relationship 
marketing activities – by which a 
company’s strategic orientations 
affect launch performance in the NPL 
context (I-II) 
4 Comprehensive 
understanding of the key 
determinants of NPL 
success, their impact on 
launch performance, and 
links to the different stages 
of product lifecycle in the 
pharmaceutical NPL setting 
What are the key 
determinants of NPL 
success, how do they 
affect launch performance, 
and how do they link to 
the innovation adoption 
curve? 
 
To identify and rank the most 
important individual determinants of 
NPL success that affect both customer 
acceptance and financial success 
measures at the different stages of the 
innovation adoption curve (III) 
5 The deeper understanding of 
the physician-pharmaceutical 
industry relationship and its 
impact on the introduction 
and prescribing of a new 
drug by physicians 
 
How can a mutually 
meaningful and beneficial 
collaboration between a 
physician and the 
pharmaceutical industry 
be built, and how is this 
relationship reflected 
when a new drug is 
introduced?  
To study the physician-
pharmaceutical industry relationship 
and interaction in order to build a 
mutually meaningful and beneficial 
collaboration between physicians and 
pharmaceutical companies, and to 
investigate how this relationship is 
reflected in introduction of a new drug 
(IV) 
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4 Methodology 
?
4.1 Design 
4.1.1 Methodological triangulation  
?
As this thesis aims to provide a comprehensive overview on the determinants of 
NPL success, it was considered valuable to combine both quantitative and qualitative 
research strategies (Figure 3). Further, the inclusion of both the seller’s and the buyer’s 
perspectives completes and deepens our understanding of the necessary determinants of 
successful product launches.  
 
Figure 3. Overall design of the study 
?
The quantitative research strategy was used to investigate the determinants of 
NPL success from a seller’s perspective in a survey study. The survey study setting was 
considered an appropriate research method since retrospective data collection has been 
the most commonly used research method in the previous NPL studies (Montoya-Weiss 
and Calantone, 1994; Di Benedetto, 1999; Calantone and Di Benedetto, 2007).  
The survey study was targeted to the pharmaceutical companies. The 
pharmaceutical industry was considered a particularly relevant empirical setting for the 
study as this industry sector is generally characterized by having high R&D intensity 
(European Federation of Pharmaceutical Industries and Associations, 2014a) and, in 
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consequence, a heavy reliance on successful NPL (Achilladelis and Antonakis, 2001). 
The pharmaceutical industry also has a strong relational business nature (Rod and 
Saunders, 2009), illustrating the B2B dynamics. Furthermore, the unique characteristics 
of the pharmaceutical industry (see chapter 1) require industry-specific knowledge 
expansion as suggested by Stremersch and Van Dyck (2009). 
The survey study was executed in Finland. The country selection was based on 
access to pharmaceutical companies; there are a reasonable number of pharmaceutical 
companies operating and launching new products in Finland and the novelty of the 
multidimensional study also guided the selection of one particular country. The cross-
sectional study setting allowed the exploration of the role of the wide-ranging 
determinants of NPL success, and the examination of their impact on launch 
performance at a certain point in time. Furthermore, this kind of survey study was 
among the first to investigate sales and marketing operations in the Finnish 
pharmaceutical industry. 
Two different quantitative multivariate data analyzing methods, namely partial 
least squares (PLS) path modeling (PLS-PM) and PLS regression modeling combined 
with target projection (PLS-R/TP), were used to analyze data from the survey study. 
PLS-PM (Wold, 1975) is a component-based structural equation modeling technique, 
which is a well-established and widely used method in marketing discipline (Hair et al., 
2012). It was considered a suitable method for explaining complex relationships. More 
specifically, the PLS-PM technique was selected in order to examine multidimensional 
and partly abstract concepts, their causal relationships and the possible mediating 
mechanisms between the concepts (Vinzi et al., 2010).  
Another multivariate data analysis method, PLS-R/TP, uses latent variable 
regression modeling and combines that with target projection. This method is 
commonly used in chemometrics (Wold, 1995). It was selected because it extracts 
relevant information from the measured correlated data (Rajalahti and Kvalheim, 2011). 
In this study, it was employed in order to explore the individual determinants of success 
(i.e. the variables) and compare their relative importance.  
Qualitative research helps us to understand a social phenomenon in its natural 
setting (Pope and Mays, 1995). Thus, a qualitative research strategy was used to 
investigate NPL from the buyer’s perspective in a theme-interview study. The theme-
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interview study was considered the appropriate research method due to nature of this 
exploratory study, which focuses on the attitudes, opinions and thoughts of individuals 
(Britten, 1996; Pope and Mays, 1996). This qualitative research method benefits from 
being able to describe and interpret social interactions and individual experiences, and 
from understanding the contexts in which these experiences are situated (O’Brien et al., 
2014). 
The interview study focused on the physician-pharmaceutical industry 
relationship. This relationship was considered a relevant and fruitful setting for this 
study since it illustrates the buyer-seller dyad in the B2B context (Wright and 
Lundstrom, 2004). Furthermore, physicians prescribe approximately 90% of all 
medicinal drug products used in Finland, accounting for the largest share of 
reimbursable medicines sales in Finland (Pharma Industry Finland, 2014b). Thus, 
physicians are the biggest customer group for the pharmaceutical industry and have a 
key role in healthcare. Thus, factors reflected in their prescribing behavior might play a 
significant role within the whole healthcare environment.  
In sum, the combination of different research strategies, perspectives and 
methods of analysis allows methodological triangulation. This mixed-method approach 
allows for the examination of the phenomenon at several different levels, and may 
support the providing of a wider overview on the studied topic (Pope and Mays, 1995). 
Methodological triangulation is also considered valuable when studying a complex and 
multifaceted phenomenon as it enables a superior interpretation of the data and 
validation of results (Hurmerinta-Peltomäki and Nummela, 2006; Jack and Raturi, 
2006). 
?
4.1.2 Survey study (I-III) 
?
The initial development of the survey items (i.e. questions) in the questionnaire 
was based on a comprehensive literature review, including both general business and 
pharmaceutical NPL literature. Existing scales were employed when applicable. The 
scale for market orientation was adapted from the cultural aspects of market orientation 
scale developed by Narver and Slater (1990). The scale for product orientation was 
adapted from Voss and Voss (2000), reflecting the overall product-centered mindset 
highlighting the importance of producing superior products, an emphasis on product 
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innovativeness, and the endeavor of offering the best product in the industry (Montoya-
Weiss and Calantone, 1994; Henard and Szymanski, 2001; Szymanski et al., 2007; 
Jaakkola, 2012). Relationship orientation was measured by utilizing the scale developed 
by Jayachandran et al. (2005), which emphasizes customer aspects of relationship 
orientation. Product advantage was studied using the scale developed by Langerak et al. 
(2004) highlighting diversely characteristics of a new product. The scale for sales force 
management was adapted from the scale developed in the NPL context by Fraenkel 
(2011). Both launch performance measures customer acceptance and NPL success, were 
based on existing scales put forward by Griffin and Page (1993, 1996).  
Two new scales were developed for measuring relationship marketing activities 
and market-based assets in the NPL context. Several steps were taken in order to 
develop valid and reliable scales for the NPL setting. Both of these new scales were 
developed based on the comprehensive review of the applicable literature to define the 
concepts and to specify their domains. The pools of the survey items in the new scales 
were created based on the insights gained from literature review. Furthermore, to ensure 
the content validity of the new scales, the selected survey items were discussed with 
industry experts.  
The survey items were assessed on a seven point Likert-type scales ranging from 
‘strongly disagree’ to ‘strongly agree’. The financial NPL success measure assessed 
how the newly launched product achieved its sales, market share and profitability. It 
was measured on an eleven point Likert-type scale ranging from ‘far below target -5’ to 
‘far above target +5’ over a one year period and a three year period (Di Benedetto, 
1999; Calantone and Di Benedetto, 2007; Droge et al., 2008). Furthermore, the overall 
measure of success assessed how successful a NPL was generally perceived and was 
measured on an eleven point Likert-type scale ranging from ‘very unsuccessful -5’ to 
‘very successful +5’ (Paladino, 2007; Droge et al., 2008). 
In addition to the survey items measuring a company’s orientations and NPL 
related activities, the questionnaire included several questions about background 
information. These questions were related to the characteristics of the respondents and 
their companies, and the selected newly launched product. 
The complete questionnaire was piloted face-to-face with seven senior-level 
directors with considerable experience in the pharmaceutical industry, representing 
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different types of pharmaceutical company and respondent categories in the sample. 
The practitioners were requested to comment on the relevance and clarity of the survey 
items, and also to openly comment on how the survey items matched their present-day 
business practices. Finally, four academic experts inspected the final pool of survey 
items to ensure that the selected items appropriately reflected the underlying concepts. 
The complete questionnaire is presented in Appendix 1.  
4.1.3 Interview study (IV) 
?
The theme-interview scheme was designed by inviting physicians to describe 
their attitudes and thoughts on the research topics using open-ended questions. The 
three themes of the interview study are presented in Table 3. The first theme, 
relationship orientation toward the pharmaceutical industry, focused on the physicians’ 
personal attitude and relationship with the pharmaceutical industry in general, and 
described the possible enhancing and inhibiting factors in the development of the 
relationship orientation of physicians to the pharmaceutical industry. The second theme, 
interaction with the pharmaceutical industry, concentrated on forms of interaction at the 
actual moment, their benefits and disadvantages, the positive and negative experiences 
of the physician-pharmaceutical industry relationship as well as a vision of the 
relationship at its best. The third theme, new drug introduction, mapped the rationale of 
physicians when considering whether to prescribe a new drug or not, and the 
accelerating and delaying factors behind their decisions.  
In addition to the interview scheme, the innovation adoption curve was utilized 
as a tool to help physicians evaluate their habits regarding new drug introduction. The 
adopter categories presented in the innovation adoption curve (Figure 2) demonstrated 
that individuals might adopt an innovation differently over time without there being any 
right or wrong way (Moore, 2002; Rogers, 2003). Physicians were asked to choose 
which adopter category they belong in and to justify their rationale for their selections. 
Furthermore, physicians’ background information was collected by using a short 
questionnaire, including questions about age, sex, specialty, working sector, years of 
experience, participation in clinical trials, frequency of meeting sales representatives 
and their opinion about being a KOL in their work unit.  
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The interview scheme, the usability of the innovation adoption curve, and the 
background information questionnaire were piloted with three physicians, who fulfilled 
the sample inclusion criteria (see chapter 4.2.2). Only minor changes were made in the 
order of questions after piloting.  
Table 3. Interview themes 
 
?
4.2 Sampling and data collection 
?
4.2.1 Procedures in the survey study (I-III) 
?
The research topics from the seller’s perspective were studied with data 
collected from the pharmaceutical companies in Finland To obtain a comprehensive 
sample, a complete list of pharmaceutical companies selling and marketing medicinal 
drug products with a license to operate in Finland was employed (Finnish Medicines 
Agency, 2012). Pharmaceutical contract research and manufacturing organizations and 
wholesalers were excluded.  
As a NPL represented the key level of analysis in the survey study, data 
collection efforts were targeted at new, individual product launches from among the 
sample companies. The launched products included only novel medicinal drug products 
with marketing authorization, thus excluding health food products, medicinal devices 
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and cosmetics. The time frame of five years for launch newness was seen as appropriate 
based on previous NPL studies (Di Benedetto, 1999; Calantone and Di Benedetto, 
2007).  
Suitable target respondents for the survey study were the key personnel in 
charge of the NPL, such as product, sales and marketing managers and directors in the 
selected companies. The target respondents were identified through a preliminary 
Internet search, followed by direct contact with the directors of the respective 
companies. To ensure that the survey was directed at appropriate and knowledgeable 
respondents, those identified were asked to rate themselves on their familiarity with 
NPL-related practices, which resulted in a list of 387 knowledgeable sales and 
marketing contacts with responsibility for NPL in their organizations.  
The survey study was executed in 2012. An Internet-based survey was sent by 
electronic mail to 357 identified respondents after the deletion of 30 respondents with 
invalid contact information. The respondents were asked to complete the survey in 
relation to the product launch in which they were most involved over the last five years.  
Followed by three reminders sent by electronic mail, the request to participate in 
the survey yielded 110 responses. After removing one response with problematic 
missing values, a total of 109 usable responses remained, representing a 30.5% response 
rate. The characteristics of the respondents are presented in Appendix 2. 
 
4.2.2 Procedures in the interview study (IV) 
?
Randomized sampling from the member register of the Finnish Medical 
Association was used to obtain a representative sample of 100 physicians in the 
geographical area of metropolitan Helsinki in Finland. Medical students, dentists, and 
veterinarians were excluded. The physicians were approached by telephone or via 
email, and the study aims and methods were explained. Physicians prescribing drugs on 
a daily basis were included in the study, which excluded retired physicians or 
physicians working in administrative, research or educational positions. Twenty-two 
physicians accepted the invitation to participate in the study (including the participants 
involved in the piloting). Further participants would have been considered, if the 
saturation point had not been achieved.  
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Interviews were conducted face to face in peaceful locations between April and 
June in 2014 by two trained researchers. The participants were asked to give their 
written consent to participation and to complete the background information form 
before the interview. The characteristics of the participants are presented in Appendix 3, 
representing well the overall population of physicians in Finland.  
The participants were encouraged to ponder the topics in-depth and describe 
their thoughts and experiences openly. The interview length varied from 30 to 45 
minutes and they were audiotaped with permission (n=20) to allow for the assessment 
of the interviewers’ reliability and to be transcribed verbatim (143 pages in total). Notes 
were taken for the two non-audiotaped interviews and they were made during and 
immediately after these interviews. Further interviews were considered unnecessary as 
the physicians’ narratives were being repeated, indicating the achievement of the 
saturation point. 
?
4.3 Analyses 
?
4.3.1 PLS path modeling (I-II) 
?
The survey study focused on the determinants of success, some of them 
representing an abstract and unobservable phenomenon (i.e. a company’s strategic 
orientation), while others were more concrete and directly observable (i.e. launch 
activity). Therefore, it is necessary to approach the measurement of the determinants 
through constructs with multiple indicators (i.e. survey items). The multi-item measures 
increase reliability compared to single-item measures as they decrease measurement 
error as the number of items in the scales increases (Henard and Szymanski, 2001; 
Szymanski et al., 2007). As the direction of the causality is from the construct to the 
indicators, and because change in the construct causes changes in the indicators, the 
classic measures are called reflective (Bollen and Lennox, 1991). Thus, the survey 
items should be internally consistent as they all reflect the same underlying construct, 
and are interchangeable meaning that construct validity does not change when a single 
indicator is removed (Bollen and Lennox, 1991). 
The selection of the constructs in studies I and II were based on the research 
questions about examining the role and impact of the strategic orientation(s) of the 
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companies on launch performance, and their possible mediating mechanisms. The 
selected constructs and measurement items (i.e. indicators) are presented in Appendix 2 
and Appendix B in the original publications I and II, respectively. 
Hypotheses were used to explain the hypothesized relationships between the 
selected constructs. All of the hypotheses are summarized in Table 4. The detailed 
reasoning that is related to the theoretical foundations of each hypothesis can be found 
in the publications. 
Table 4. Hypotheses in study I and II 
 
Two conceptual models were used to illustrate the selected constructs and their 
hypothesized relationships. More specifically, the conceptual model was used to test the 
proposed hypotheses. The conceptual model used in study I examines the role and 
impact of the three companies’ strategic orientations on launch performance, while two 
mechanisms, namely product advantage and market-based assets, explain how a 
company’s orientations can concretely influence launch performance (Figure 4). The 
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conceptual model used in study II examines the impact of relationship orientation on 
launch performance, and includes sales force management and relationship leveraging 
activities as two potential key mediators for explaining how the relationship orientation 
of a company can affect launch performance (Figure 5). 
 
 
Figure 4. Conceptual model of the study I 
 
? 
Figure 5. Conceptual model of the study II 
 
The conceptual models and hypotheses were tested by employing PLS-PM by 
means of the SmartPLS 2.0 software application (Ringle et al., 2005). PLS-PM was 
employed as it can achieve high levels of statistical power, even if the sample size is 
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relatively small at approximately 100 observations and if the measurement model 
quality is good (i.e. loadings >.70; Reinartz et al., 2009). Furthermore, PLS-PM is well 
suited to the aims of this study as the main focus lies in explaining the variance of the 
endogenous constructs (Hair et al., 2012). PLS-PM can also model latent constructs 
under conditions of non-normality, which was the case in this research (Chin et al., 
2003). The minimum sample size in PLS-PM should be ten times the highest number of 
formative indicators in one construct or the largest number of paths connecting the 
exogenous variables to one endogenous variable, and this study meets that condition 
(Hair et al., 2012). A bootstrapping procedure was employed to test the significance of 
the PLS parameter estimates, based on a sample size of 5,000 as recommended by Hair 
et al. (2012).  
As the hypothesized mediating effects represent a central aspect of the 
conceptual models, the mediating effects are tested according to the process developed 
by Baron and Kenny (1986). The examination of the mediators’ hypothesized outcomes 
is limited to customer acceptance representing customer-based performance, so as to be 
able to explore the mediating effect in detail. In order to establish mediation, the 
following conditions must be met. Firstly, the independent variable (i.e. construct) must 
significantly account for the variations in the presumed mediator; second, the mediator 
must affect the dependent variable (i.e. success measure); and third, the independent 
variable must be shown to affect the dependent variable. If all of these conditions hold 
in the predicted direction, mediation occurs when the effect of the independent variable 
(c) on the dependent variable (c’) is reduced when the mediator variable is added to the 
model.  
?
4.3.2 PLS regression modeling combined with target projection (III) 
?
The whole data set collected in the survey study was subjected to PLS-R/TP 
analysis using latent variable methods to reveal the most informative variables (i.e. 
success determinants). The analysis was performed using Sirius version 9.0 software 
(Pattern Recognition Systems AS, Bergen, Norway). The variables were partitioned into 
predictor (input) and response (output) variables as presented in Appendix 4. 
Principal component analysis (PCA) was first performed to obtain an overview 
of the data and to reveal possible clustering, trends and outliers among the variables and 
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respondents (Jackson, 1991). PCA confirmed that the data had no outliers and revealed 
that the overall success measure provided a good description of both one year and three 
year financial success measures, and thus it could be used to summarize the financial 
response measures. 
 PLS regression models were then calculated for each response variable 
separately (Wold et al., 1984). In order to improve the interpretation of the PLS models, 
a target projection (TP) was performed (Kvalheim and Karstang, 1989; Rajalahti and 
Kvalheim, 2011). In this projection, the predictor variables matrix is projected onto the 
PLS regression vector. The information in the predictor data that is unrelated (i.e. 
orthogonal) to the response variable is thus removed and a single latent variable (i.e. a 
target-projected component) is obtained. The TP component represents the predictive 
information in the predictor variables for the investigated response variable.  
The calculation of selectivity ratios (SR) was used to reveal the most 
informative predictor variables for each investigated response variable (Rajalahti et al., 
2009a and 2009b). The SR is defined as the ratio between explained variance and 
residual (unexplained) variance in the target-projected component, and is calculated for 
each predictor variable. This ratio represents a direct quantitative measure of the 
importance of a predictor variable to explain and predict the response variable. 
Furthermore, by multiplying the SR with the sign of the corresponding loading on the 
target-projected component, the SR value reveals which response variables increase and 
which decrease with the rising values of the predictor variables. The size of the SR 
ranks the most important predictor variables contributing to the different response 
variables (Kvalheim et al., 2014). In other words, SR operates as a sensitive 
multivariate index to rank predictor variables according to their importance in the latent 
variable model. The predictor variables with a high (positive or negative) SR value are 
best at explaining the behavior of the investigated response variables.  
In this study, the SR values were calculated for each predictor variable in each 
separate TP model (i.e. for all response variables separately). The response variables 
that increase with the increasing predictor variable provide positive SR while those 
decreasing with the increasing predictor variable provide negative SR. Furthermore, 
confidence intervals were calculated for each SR value based on the iterative cross-
validation procedure explained earlier.  
? 47 
4.3.3 Content analysis (IV) 
?
The content of the interviews were analyzed inductively (Pope et al., 2000; Elo 
and Kyngäs, 2008; Pope and Mays, 2009). Inductive content analysis aims to achieve a 
condensed description of the studied phenomenon from textual data based on providing 
categories, which describe the previously unstudied or partially understood 
phenomenon (Elo and Kyngäs, 2008). In other words, the research direction flows from 
data toward generalizations in comparison to the deductive content analysis, which aims 
to test the previous theory or model in a different context (Pope and Mays, 1995; Elo 
and Kyngäs, 2008). Furthermore, an outcome of the systematic inductive content 
analysis aims to provide typology and find associations between the studied themes in 
order to interpret the findings (Pope et al., 2000).  
Two researchers read through the entire data a number of times to obtain an 
overall impression of each interviewee’s narrative. The open coding of the data was 
then done manually to describe all aspects and variation in the data as comprehensively 
as possible in relation to the selected research question: how can a mutually meaningful 
and beneficial relationship and interaction between physician and pharmaceutical 
industry be built, and how is this relationship reflected in new drug introduction. The 
separate lists of identified items compiled by both researchers were compared and 
grouped under higher order categories to decrease the number of items, following a 
discussion of similarities and dissimilarities.  
Based on the first phase of coding, three exclusive main categories and their 
subcategories were identified and used as a basis for further coding: 1) the relationship 
orientation of physicians, including positive, neutral, and negative attitudes toward the 
pharmaceutical industry; 2) the interaction of physicians with pharmaceutical 
companies, including the intensity of interaction (activity/passivity); 3) new drug 
introduction by physicians, including immediate, early, and late adoption patterns. Two 
researchers then coded the data as a whole by working in parallel and individually and 
by using the qualitative data analysis software (ATLAS.ti, Scientific Software 
Development GmbH, Berlin, Germany). The consistency of the coding between the 
researchers was compared, discussed and revised until mutual agreement was achieved.  
 
?
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4.4 Reliability and validity 
?
4.4.1 Quantitative analyses (I-III) 
?
Reliable and valid scales and measures provide the basis for trustworthy 
research. Several steps were taken to ensure the reliability and validity of the multi-item 
scales (I-II) and the multivariate data analyzing methods (I-III). The initial validity 
assessment for the constructs (I-II) was conducted with exploratory factor analysis by 
employing PCA. After the elimination of a few problematic indicators (i.e. survey 
items), the PCA supported the validity of the constructs as all the survey items loaded 
highly (i.e., >0.40) on the theoretical factor, and no problematic cross-loadings greater 
than 0.40 on the other factors were found to exist (Hinkin, 1995). The elimination of 
indicators is acceptable for reflective constructs due to their interchangeable nature 
(Bollen and Lennox, 1991). Regarding the PLS-R/TP analysis (III), the PCA confirmed 
that the data had no outliers.  
The further reliability and validity assessments (I and II) included Cronbach’s 
alpha and composite reliability for assessing the reliability of the internal consistency 
(i.e. how well the indicators measure the same topic). The construct reliability was 
supported as all constructs exceeded the recommended threshold (>0.50), except the 
construct of market orientation in article I, which was 0.49. Convergent validity (i.e. 
how the measures are related) was assessed by using average variance extracted (Hair et 
al., 2012), and this was supported as all the constructs exceeded the recommended 
threshold. Discriminant validity (i.e. how measures are unrelated) was evaluated using 
the Fornell-Larcker (1981) criterion and indicator cross-loadings. These requirements 
were met, as the square roots of average variance extracted for all constructs were 
greater than for the corresponding correlations with any other construct. Also the 
indicator cross-loadings for each construct showed that each indicator loads highest on 
the construct it is intended to measure, indicating further support for discriminant 
validity (Hair et al., 2012). The detailed scale properties can be seen in Table I and 
Table 1 in the original publications of I and II, respectively. 
Furthermore, the requirements for indicator reliability were met since all 
indicator loadings were statistically significant (i.e., p<0.001), and mostly exceeded the 
recommended threshold of 0.70 (Hair et al., 2012). However, the four loadings (I) 
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below the 0.70 level exceed the acceptable minimum level of 0.55 (Falk and Miller, 
1992). The individual indicator loadings are presented in Appendix 2 and Appendix B, 
and the individual cross-loadings are presented in Appendix 3 and Appendix C in the 
original publications I and II, respectively.  
Furthermore, the predictive validity (i.e. how well the constructs predict the 
dependent variables) of the conceptual models (I-II) were assessed by examining 
Stone-Geisser’s Q2 for the individual constructs (Geisser, 1974; Stone, 1974; Hair et al., 
2012) and the overall goodness of fit (GoF) value for the complete conceptual model 
(Tenenhaus et al., 2005). These assessments demonstrated a sufficient level of 
predictive relevance in the NPL context (Hair et al., 2012). The detailed values for 
predictive validity assessment can be seen in the original publications I and II. In 
addition to having satisfactory validity and reliability statistics, the novel scales of 
relationship marketing activities and market-based assets demonstrated high predictive 
validity as they explained launch performance reasonably strongly, giving further 
support to the goodness of fit of these new measures (see Table II and Figure 2 in the 
original publications I and II, respectively). 
In the case of PLS-R/TP analysis (III), the repeated double cross-validation was 
used to estimate the number of PLS components in order to obtain the PLS models with 
the best predictive performance (Bro et al., 2008). In this procedure, one subset (here 
one-seventh part of the observations) at a time was randomly removed from the training 
set. A PLS model was calculated using the remaining data and subsequently employed 
to predict the removed subset. By repeating this procedure several (here 100) times, all 
observations were utilized both for training and external validation and the 
measurement of a model’s predictive performance was obtained. Furthermore, the 
explained variances for the PLS models showed the presence of a response related 
factor in the predictor variables. The percentage explained the variances for the PLS and 
the TP models that were used as one measure of the overall predictive performance of 
the model and are presented in details in Table 3 in the original publication III.  
As the survey study design might result in some biases, possible non-respondent 
bias was assessed employing a t-test of the difference in means on the constructs 
(Armstrong and Overton, 1977). The t-test comparison between early and late 
? 50 
respondents revealed no significant differences in means between these respondent 
groups at the p=<0.05 level, indicating the absence of systematic non-response bias. 
Common method bias needs to be taken into account when both independent 
and dependent variables are obtained from the same source. This is the case in this 
study as it is based on cross-sectional single respondent design due to the evident 
challenges in obtaining wide-ranging access to companies. Several procedural remedies 
were employed consistently with recommendations made by Podsakoff et al. (2003) 
including full anonymity concerning responses and the employing of various types of 
scale format and anchor. Furthermore, common method bias was assessed by Harman’s 
one factor test, which is the most widely employed technique to address common 
method variance (Podsakoff et al., 2003). The un-rotated factor analysis indicated that 
common method bias is unlikely to be a serious concern in this study (see the original 
publications I and II). 
As the data was collected retrospectively some halo effect bias may exist, since 
the success or failure of each product launch was known prior to answering the survey. 
A subjective evaluation might result in an overoptimistic assessment of launch success 
if respondents are unwilling to admit the failure of a new product (Henard and 
Szymanski, 2001; Szymanski et al., 2007). In order to minimize this limitation, the 
respondents were carefully selected to represent those who are the most familiar with 
and involved in the launch of a new drug. The objective verification of financial NPL 
success in comparison to actual sales data could be valuable but it was not possible in 
this study due to the strict confidentiality restrictions of the pharmaceutical companies.  
In conclusion, the results from the reliability and validity assessments, and the 
evaluations of the possible biases indicate that the multi-item scales and the overall 
survey study design had satisfactory reliability and validity. 
 
4.4.2 Qualitative analyses (IV) 
 
The reliability and validity of the interview study was taken into account in the 
design phase of the study in collaboration with a methodological expert in qualitative 
research. Reliability and validity were assessed several ways during the data collection 
and analyzing phases. The reliability was confirmed by involving two trained 
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researchers in the interviews, allowing one to interview and one to observe. The 
audiotaping and transcription of the interviews allowed the researchers’ reliability to be 
assessed.  
Two researchers also conducted the content analysis parallel and individually. 
The consistency of the coding between the researchers was compared, discussed, and 
revised until mutual agreement was achieved, thus increasing the reliability of the 
analysis. Finally, the preliminary conclusions of the results were sent to the participants 
for review. This additional validation step did not yield any criticism of the researchers’ 
interpretation of the results.  
Furthermore, the randomized sampling across the setting (i.e. the public and 
private health care units) and across the disciplines (i.e. physicians with various 
backgrounds) increases the validity of the interview study. The characteristics of the 
participants indicated a good fit with the statistics of the Finnish physicians (Finnish 
Medical Association, 2015). Furthermore, representative, authentic and anonymous 
citations were used to increase the trustworthiness of the study and to exemplify the 
original data from which the categories were formed (Elo and Kyngäs, 2008). 
 
4.5 Ethical considerations  
 
The ethical considerations of the interview study (IV) were taken into account 
by requesting an ethical review statement from the University of Helsinki Ethical 
Review Board in the humanities, social and behavioral sciences before the study began. 
The review board stated that the study is ethically acceptable (Statement 14/2014).  
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5 Results and discussion 
?
5.1 Role and relative impact of a company’s strategic orientations (I-
III) 
?
5.1.1 Relationship orientation as a complementary strategic orientation (I-III) 
?
The first aim of this study was to examine the role and relative impact of three 
alternative strategic orientations – market orientation, product orientation and 
relationship orientation – on launch performance. The results of the direct effects from 
PLS-PM (I and II) for each studied orientation (as constructs) are presented in Table 5, 
summarizing the standardized path coefficients, their t-values, statistical significances 
and explained variance R2.  
 
Table 5. PLS path modeling results of the direct effects on the orientations 
 
The results demonstrate a strong positive link between relationship orientation 
and both studied areas of launch performance. This finding broadens the established 
positive link between a company’s relationship orientation and general business 
performance (Yau et al., 2000; Sin et al., 2002; Sin et al., 2005a; Winklhofer et al., 
2006; Stewart et al., 2012; Salojärvi et al., 2015) to launch performance, including both 
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customer acceptance and financial launch performance measures. Both of these studied 
measures were positively related, demonstrating that customer acceptance is a central 
predictor of the financial performance of a NPL. Importantly, the identified relationship 
orientation – performance link is the strongest one of the three studied orientations (cf. 
Yau et al., 2000). The finding provides evidence of the significant role of relationship 
orientation in launch performance in comparison to a company’s other strategic 
orientations. 
Simultaneously, the results of the PLS-R/TP analysis for each individual 
orientation-related variable are summarized in Figure 6. All selectivity ratios with their 
confidence intervals are presented in Appendix 5. The most significant SR values are 
linked to the relationship orientation-related variables especially in terms of the 
acceptance of the majority of customers. The variables with the highest SR values 
include a company’s willingness to invest in building customer relationships, the 
treatment of customers with both empathy and reciprocity, as well as trust between a 
company and its customers. 
The similar results provided by both methods of analysis strengthen the finding 
that the relationship orientation is a key success factor in the launching of a new 
product. Theoretically, the effect of relationship orientation on customer acceptance can 
be explained due to lowered innovation diffusion barriers (Talke and Hultink, 2010b), 
resulting from, for instance, higher customer participation and efforts to establish 
stronger relationships with customers (Fang, 2008). 
The strong impact of relationship orientation on launch performance makes a 
substantial addition to existing mainstream NPL studies, which have mainly applied a 
product-centered or marketing mix perspective when considering effective strategic and 
tactical launch activities (e.g. Calantone and Di Benedetto, 2007; Evanschitzky et al., 
2012). Furthermore, the finding extends current knowledge concerning the role of a 
company’s strategic orientations when launching new products (e.g. Langerak, 2003; 
Langerak et al., 2004; Talke and Hultink, 2010a). The existing research is largely 
limited to investigating the role of a company’s general customer and competitor focus 
through the concept of market orientation for new product performance (e.g. Langerak, 
2003; Langerak et al., 2004; Talke and Hultink, 2010a; Mu and Di Benedetto, 2011), 
whereas this research provides a relational explanation for launch performance.  
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Figure 6. Selectivity ratios for orientation-related variables (abbreviations of the 
variables are explained in Appendix 4) 
?
The finding is also aligned with the pioneering commercialization studies that 
highlight the importance of networks in innovation diffusion in the B2B context (e.g. 
Makkonen and Johnston, 2014) and in the commercialization of radical innovations 
(Story et al., 2011; Aarikka-Stenroos et al., 2014; Aarikka-Stenroos and Lehtimäki, 
2014; Sandberg and Aarikka-Stenroos, 2014;). Furthermore, this finding supports the 
broader business marketing studies that have stressed an ongoing transition toward a 
more relational approach in business, as opposed to acting solely as suppliers according 
to the traditional sales-oriented approach presented in the general marketing and sales 
literature (e.g. Möller and Halinen, 2000). While relational approaches are considered 
important in the management of existing long-term B2B clientele, it is a novel and 
much less intuitively self-evident finding that it is also a key determinant in the 
successful implementation of NPL. 
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In summary, the finding emphasizes that the development of long-term 
relationships with a company’s customers and other key stakeholders is a key success 
factor in the launching of a new product. Therefore, relationship orientation is not only 
important in the management of existing long-term B2B exchange but also represents 
an additional central predictor of launch performance. In addition to sensing markets, 
gathering customer and competitor knowledge and responding to market information, 
companies benefit from paying explicit attention to relationships when launching new 
products.  
?
5.1.2 Product orientation and market orientation (I, III) 
?
The PLS-PM results demonstrate that market orientation has a positive direct 
effect on customer acceptance but offers only weak support for financial performance 
regarding NPL (Table 5). These results align with the extant broad research evidence 
(e.g. Langerak et al., 2004; Kirca et al., 2005; Paladino, 2007). In contrast, the SR 
values show that a few of the market orientation-related variables had more impact on 
the financial success measure than on the customer acceptance measures (Figure 6). 
However, the magnitude of the SR values in the market orientation-related variables is 
much lower compared to the relationship orientation-related variables. 
This finding indicates that the broadly studied concept of market orientation, 
emphasizing a company’s focus on customer’s satisfaction and competitors (Kirca et 
al., 2005; van Raaij and Stoelhorst, 2008), is not sufficient in explaining the role of a 
customer’s acceptance regarding NPL success. In addition, some researchers have 
argued that an overemphasis on customer needs might decrease a company’s innovative 
competence and therefore lead to only marginally new products (Langerak, 2003; 
Langerak et al., 2004; Zhou et al., 2005).  
In turn, a company’s product orientation positively affects customer acceptance 
but not financial performance (Table 5). This positive link matches earlier findings from 
consumer settings (Voss and Voss, 2000) and the NPL context (Mu and Di Benedetto, 
2011). However, the impact of product orientation on launch performance was lower 
compared to the other orientations that were examined. Similarly, the product 
orientation-related variables demonstrated the lowest SR values of all the performance 
measures (Figure 6). 
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Interestingly, the statistically not significant link between product orientation 
and launch performance supports the findings of a meta-analysis concluding that the 
innovation-performance relationship is context dependent (Rosenbusch et al., 2011). 
Although the pharmaceutical industry sector selected for this study focuses heavily on 
R&D, a product-oriented company’s mindset is seemingly inadequate on its own for 
achieving launch performance because the empirical findings emphasize the role and 
importance of complementary strategic orientations (cf. Mu and Di Benedetto, 2011).  
?
5.2 Relationship orientation of buyers and its antecedents (IV) 
 
The second aim of this thesis was to study the attitudes of physicians toward the 
pharmaceutical industry as reflected in their relationship orientation, and to identify the 
antecedents affecting the development of their relationship orientation. The concept of 
relationship orientation was studied on the basis of how physicians described their 
opinions and thoughts about their relationship with the industry in general. These 
attitudes reflected the physicians’ relationship orientation, which was then categorized 
as a positive, neutral, and negative relationship orientation. The detailed descriptions 
and the illustrating quotations of each category are presented in Appendix 6.  
The closer examination of the concept of relationship orientation from a 
physician’s perspective contributes to both the existing medical and business literature. 
Firstly, it deepens the current understanding of physicians’ attitudes toward the 
pharmaceutical industry as an antecedent of the physician-pharmaceutical industry 
relationship. As the relationship orientation refers to a desire to engage in a relationship 
(Palmatier et al., 2008), it helps to describe the physicians’ overall attitude toward the 
pharmaceutical industry instead of focusing on single factors such as sales 
representatives, gifts and samples (e.g. Manchanda and Honka, 2005). The identified 
three categories of relationship orientation align with the findings Doran et al. (2006) 
made when researching specialists.  
Secondly, the concept of relationship orientation allows the findings to be linked 
to business literature, as Palmatier et al. (2008) have demonstrated that a buyer’s 
relationship orientation determines the effectiveness of relationship marketing. The 
physicians described both enhancing and inhibiting factors, which affected the 
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development of their relationship orientation toward the pharmaceutical industry (Table 
6). These antecedents are consistent with previous literature (Lagace et al., 1991; 
Andaleeb and Tallman, 1995; Palmatier et al., 2008), but distinguish a dependence on 
novel information instead of on product dependence as an antecedent of the relationship 
orientation (Palmatier et al., 2008) in the medical B2B context. 
Table 6. Antecedents of a physician’s relationship orientation to the pharmaceutical 
industry 
 
5.3 Implementation of a company’s strategic orientations (I, II) 
?
5.3.1 Comparison of mediating mechanisms among strategic orientations (I) 
 
The third aim of this study was to investigate the alternative mediating 
mechanisms by which a company’s strategic orientations affect customer acceptance in 
the NPL context. Firstly, the results for each studied orientation that are related to the 
two mechanisms, product advantage and market-based assets, from PLS-PM (I) are 
presented in Table 7, summarizing the standardized path coefficients, their t-values, 
statistical significances and explained variance R2.  
The results reveal that all the examined orientations affected positively customer 
acceptance but through different mechanisms. The impact of market orientation and 
relationship orientation on customer acceptance is partially mediated through market-
based assets, whereas the impact of product orientation is fully mediated through 
product advantage. These findings broaden the focus of NPL research, which has thus 
far concentrated on product advantage as the key mediating construct in explaining how 
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a company’s strategic orientations affect launch performance (e.g. Langerak et al., 
2004). Furthermore, a broader understanding of the mediating mechanisms helps to 
perceive as well as implement the strategic orientations instead of remaining as abstract 
and vague upper-level conceptual mindsets.  
Table 7. PLS path modeling results of the mediating effects of the orientations 
 
The empirical results show that the accumulated market-based assets form an 
alternative powerful mediator linking a company’s strategic orientations and launch 
performance, which parallels earlier studies focusing on general business performance 
(e.g. Srivastava et al., 1998; Rust et al., 2004; Kirca et al., 2005; Grewal et al., 2009; 
Ramaswami et al., 2009; cf. Kleinschmidt et al., 2007). More specifically, both 
relationship orientation, emphasizing the importance of customer relationships, and 
market orientation, underlining general customer and competitor focus, improve launch 
performance by helping companies to accumulate market-based assets such as loyalty, a 
broad customer base and the generating of brand preferences. Thus, the market-based 
assets provide a relational perspective on launch performance through established 
customer relationships, which act as a central means for lowering customer adoption 
barriers for innovation as was suggested by Talke and Hultink (2010b). This finding 
also gives support to the idea that undeveloped relational networks can act as a central 
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diffusion barrier to innovations in B2B contexts (Sandberg and Aarikka-Stenroos, 
2014). 
Furthermore, the results confirm the role of product advantage as a critical 
success factor in the NPL context (cf. Henard and Szymanski, 2001). This link builds 
on the theory of innovation diffusion stating that product advantage enhances customer 
adoption and the diffusion of innovation (Rogers, 2003). However, product orientation 
is the only strategic orientation that links to customer acceptance through an increase in 
product advantage. In contrast to earlier findings, market orientation did not affect the 
generation of product advantage in a positive way (Langerak et al., 2004). This implies 
that although the direct link between a company’s product orientation and financial 
NPL success is not statistically significant (Table 5), companies should not 
underestimate its role in long-term business performance as product orientation helps 
companies to build product advantage and thus customer acceptance. Furthermore, the 
positive link between product orientation and product advantage, but not between 
market orientation and product advantage, implies that a company’s internal product 
focus can be more important for establishing product advantage than a market-oriented 
focus in highly R&D intensive and innovation-driven industries such as 
pharmaceuticals. In these settings, the focus on keeping customers and competitors 
close does not necessarily result in the development highly of innovative products. 
Rather, a product-oriented culture combined with a relationship approach is needed for 
long-term success. Hence, the finding broadens the demonstrated synergistic effect of 
technology and customer relationship orientations in general business performance 
(Salojärvi et al., 2015), showing the benefits of having a combination of alternative 
strategic orientations in the NPL context.  
 
5.3.2 Implementation of the relationship orientation (II) 
 
Secondly, the key activities, namely sales force management and relationship 
marketing activities, through which an abstract relationship-oriented organizational 
culture transforms into launch performance, were studied. The results of the mediating 
effects from PLS-PM (II) are presented in Table 8, summarizing the standardized path 
coefficients, their t-values, statistical significances and explained variance R2. The 
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results illustrate four different mediating effects, indicating that the relationships among 
the studied constructs were more complex than hypothesized, as the findings showed 
two additional non-hypothesized mediating effects. All the mediating effects are 
presented in the complete research model in Figure 7. 
Table 8. PLS path modeling results of the mediating effects on relationship orientation 
?
??????????Mediating effects on relationship orientation 
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The first and second mediating effects demonstrate that both sales force 
management and relationship marketing activities play key roles in transforming a 
company’s abstract relationship orientation into customer acceptance. More 
specifically, the findings show that relationship orientation has a major influence on a 
company’s sales force management practices in NPL, such as controlling and rewarding 
the sales force; thus supporting notions concerning the relational role of sales in 
business markets (e.g. Storbacka et al., 2009). Furthermore, a company’s relationship 
orientation is a central driver of the systematic leveraging of customer and stakeholder 
relationships in NPL. These activities highlight issues such as the identification and 
involvement of opinion leaders; the efforts to build pre-launch product awareness 
among key stakeholders by involving potential early adopters; the various market 
access-focused activities aimed at stakeholders, gatekeepers who can have a major 
impact on the adoption of new products, and also the systematic building of long-term 
relationships with key customers and stakeholders (e.g. Mantrala et al., 2008). 
The third mediating effect shows that sales force management has a critical role 
in transforming a company’s abstract relationship orientation into concrete relationship 
marketing activities (Figure 7). Much of the extant new product selling literature has 
examined issues such as sales force composition, effort and commitment to new 
products, motivation and training, and considers a sales force a critical contributory 
factor to launch success (e.g. Cooper, 1998; Di Benedetto, 1999; Hultink and Atuahene-
Gima, 2000; Fu et al., 2010). This finding provide a significant addition to the existing 
knowledge by showing that systematic sales force management is a key antecedent for 
effective relationship marketing activities when launching new products. Hence, in 
accordance with organizational culture-related research (Deshpandé et al., 1993; 
Moorman, 1995; Day, 2000), the desired outcomes, such as customer acceptance of a 
new product, and the means to achieve those desired outcomes, such as relationship 
marketing activities, should be confirmed and reinforced by communicating with and 
rewarding sales management.  
The fourth mediating effect demonstrates that relationship marketing activities 
mediate the effect of sales force management on customer acceptance (Figure 7). This 
finding emphasizes the utmost importance of relationship marketing activities in the 
NPL context, aligning it with the modern perspective that salespersons should recognize 
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their role as relationship builders (e.g. Crosby et al., 1990; Jolson, 1997; Weitz and 
Bradford, 1999), and more broadly emphasizes the increasingly relational role of selling 
(cf. Storbacka et al., 2009; Haas et al., 2012).  
In summary, the mediating effects that were found indicate how a company’s 
abstract relationship-oriented organizational culture is transformed into launch 
performance. In fact, the results confirm that a company’s relationship orientation and 
the identified mediating mechanisms are the central predictors of performance in the 
NPL context. 
?
5.4 Diversity of success drivers in NPL (III) 
?
The previous chapter illustrated the diversity of the theoretically hypothesized 
mechanisms, which predict a company’s launch performance by putting the abstract 
organizational culture-related orientations of a company into practice. The fourth aim of 
this study is to investigate the NPL-related success factors. In fact, the aim is to explore 
comprehensively the determinants of NPL success by identifying and ranking the most 
important individual success drivers affecting customer acceptance and financial 
performance measures along the innovation adoption curve. 
The results of the PLS-R/TP analysis for each individual variable, including 
product advantage, strategic choices, tactical decisions, sales force management, 
relationship marketing activities and market-based assets, are summarized in Figure 8. 
All selectivity ratios with their confidence intervals are presented in Appendix 5. The 
results distinguish between the determinants driving financial success and those driving 
customer acceptance – as related to both KOL and the majority of target customers in 
the NPL setting. Whereas financial success is driven by strategic choices and tactical 
decisions, product advantage and relationship marketing activities contribute to 
achieving key opinion leaders’ acceptance, while the accumulated market-based assets 
largely determine the acceptance of a majority of other target customers.  
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Figure 8. Selectivity ratios for product advantage, sales and marketing decisions and 
activities related to the variables (abbreviations of the variables are explained in 
Appendix 4) 
?
Further analysis utilized the innovation adoption curve and provided deeper 
knowledge about customer acceptance at the different phases of innovation diffusion in 
the NPL context. The summary of the highest SR values (> .4) reveals that the 
relationship approach is vital for fostering customer acceptance at different phases of 
innovation diffusion (Figure 9). A summary of the success drivers and the individual 
key determinants are also presented in Table 5 in the original publication III. 
In the early phase, the product advantage and relationship marketing activities 
are the key determinants of NPL success, demonstrating their importance for achieving 
the acceptance of KOLs, which shows that they appreciate the benefits and superiority 
of the product over its competitors, which is logical, since product advantage is one of 
key factors driving the speed of innovation (Rogers, 2003). The highest SR values also 
demonstrate that relationship marketing activities, which aim to establish, maintain and 
leverage customer relationships, are more valuable for KOLs than the traditional 
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marketing mix and sales activities in the early phase of launch. This finding contributes 
to the extant literature by demonstrating the significance and effectiveness of 
relationship marketing in this specific target customer group in the pharmaceutical NPL 
context (Talke and Hultink, 2010b; Athaide and Zhang, 2011). Thus, the effective 
engagement of KOLs is an important antecedent for the market penetration of a new 
drug (Sandberg, 2002; Smith, 2009).  
 
 
Figure 9. Variables with selectivity ratios over 0.4 (abbreviations of the variables are 
explained in Appendix 4) 
 
In the later phase of innovation diffusion, in addition to the relationship-oriented 
organizational culture (see chapter 5.1.1), the accumulated market-based assets largely 
determine a new product’s acceptance by the majority of other target customers, 
representing the mainstream market segment. The rationale behind the differences in the 
key success determinants of the early and late customer groups lies in the innovation 
diffusion theory, which puts forward the view that the domains of greatest value to 
customers change from technology- and product-related aspects to market- and 
company-related aspects as a new product moves through its lifecycle (Moore, 2002).  
Furthermore, as the results show, certain strategic choices, such as 
comprehensively gathered market intelligence and a clearly defined launch strategy, and 
Product advantage (PA) and 
relationship marketing (RM) 
activities for KOLs 
Relationship orientation (RO) 
and market-based assets (MBA) 
for the majority of customers 
Tactical decisions (TAC) and  
strategic choices (STR) 
for financial success 
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tactical decisions, such as appropriate pricing policy and price level, a well conducted 
promotion and a proficiently executed marketing plan, drive the financial success of a 
new pharmaceutical product launch. However, the timing of the product launch seems 
to be the most important strategic variable for gaining acceptance from both KOLs and 
the majority of customers. These findings support previous studies that present these 
determinants as the key elements in NPL success (Hultink et al., 1997; Di Benedetto, 
1999; Trim and Pan, 2005; Amsbaugh and Pitta, 2006; Stros et al., 2009; Stros and Lee, 
2014).  
Interestingly, the role of sales force management activities is less significant 
than expected – based on the previous literature (Ruzicic and Danner, 2007; Fraenkel, 
2011) and compared to the results of the PLS-PM. A similar phenomenon can be seen 
in relation to the market access strategy and tactical activities, such as advance 
notification documentation to key decision-makers, health outcome toolkits and 
implementation tactics. They had a moderately low impact on NPL success in this data 
set, although the role of market access has been noted as essential for the launch of a 
new drug (McGrath, 2010).  
In summary, the results distinguish between different success factors at different 
phases of innovation diffusion and emphasize the significance of the relationship 
approach in the launch of a new product. The key role of the relationship approach can 
be seen at a company’s organizational culture level but also at the level of concrete sales 
and marketing activities.  
?
5.5 New product introduction and physicians (IV) 
?
The fifth and the last aim of this thesis was to study the physician-
pharmaceutical industry relationship in order to build a mutually meaningful and 
beneficial collaboration, and to investigate how this relationship is reflected when a new 
drug is introduced. The adoption patterns and rationale of the physicians in new product 
introduction were studied by utilizing the innovation adoption curve and adopter 
categories. The identified categories, based on the content analysis and the illustrating 
quotations, are presented in Appendix 6. 
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5.5.1 Rationale in new product introduction  
 
The results of the content analysis revealed that product advantage and a 
physician’s personal interest were the main accelerating adoption factors in the early 
adopter categories, whereas evidence- and experience-based reasoning and colleagues’ 
opinions were the most common reasons for a new product introduction in the late 
adopter categories (Table 9). In other words, the rationale for physicians to introduce a 
new drug is related to superior product characteristics, a physician’s personal interest, 
and new drug information. Although these aspects have been widely acknowledged 
(Groves et al., 2002; Buusman et al., 2007; Jaakkola and Renko, 2007; Mason, 2008), 
none of the previous studies has linked physicians’ prescribing rationale with the 
adopter categories used in the theory of innovation diffusion. This novel information 
helps the pharmaceutical industry to better understand a new product introduction from 
the perspective of physicians and to better serve their needs during the different phases 
of a product’s lifecycle. 
Table 9. The rationale of physicians when introducing a new drug 
 
Unexpectedly, 45% of the physicians selected two adopter categories instead of 
one indicating a dual adoption approach regarding new drugs. These physicians 
described a different rationale for introducing new products in different situations. In 
fact, these physicians prescribed a new drug both in the early phase (innovators, early 
adopters) and in the later phase (late majority, laggards) of the innovation adoption 
curve (Appendix 6). The identified bipolar rationale behind the introduction of a new 
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product in different situations seems to occur due to the differences in the properties of 
a new drug, the personal interests of physicians and their specialties. In fact, for 
example, those specialists who adopted an innovative new drug that catered to a clearly 
unmet medical need delayed or even ignored a new generic drug outside their specialty.  
5.5.2 Physicians’ relationship orientation to the pharmaceutical industry and new 
product introduction 
 
The content analysis revealed how the physicians’ relationship orientation was 
reflected in their new product introduction through interaction with pharmaceutical 
companies. More specifically, the physicians’ positive relationship orientation and 
active interaction was reflected in the early adoption of a new drug, whereas the 
negatively oriented and passively interacting physicians adopted a new drug later. These 
two main pathways linking the physicians’ relationship orientation, interaction and new 
product introduction are illustrated in Figure 10. 
 
 
 
 
 
 
 
 
 
 
Figure 10. Two pathways linking the relationship orientation of physicians to the 
pharmaceutical industry, their interaction with it and the introduction of new products  
 
The intensity of the physicians’ interaction has previously been observed from 
mainly ethical perspectives (Brennan et al., 2006; Doran et al., 2006) due to the 
criticism of physician-pharmaceutical industry relationships. The results emphasize that 
the physicians’ primary needs for interaction are related to professional development 
and drug information instead of unprofessional personal benefits (Figure 11 and 
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Appendix 6), which have been used to entangle physicians and pharmaceutical 
companies (Abbasi and Smith, 2003; Moynihan, 2003b; Brennan et al., 2006). This 
finding indicates that the physician-pharmaceutical industry relationship has developed 
from being ethically precarious and having non-professional personal benefits toward 
becoming a more sustainable collaboration. Furthermore, the physicians’ perspectives 
outline the elements necessary for a mutually meaningful and beneficial physician-
pharmaceutical industry relationship and collaboration.  
 
 
Figure 11. Perceived benefits and challenges for physicians when interacting with 
pharmaceutical companies 
 
In comparison to the previous studies, this study extended its analysis from the 
orientation-interaction linkage to new drug introduction (cf. Doran et al, 2006). The 
adoption patterns of physicians were analyzed on the basis of their willingness to 
introduce a new drug. These adoption patterns were categorized into immediate, early 
and late adopters. The descriptions and the illustrating quotations for each category are 
presented in Appendix 6.  
The interlinkages between the research themes (i.e. a physician’s relationship 
orientation, interaction and new product introduction) in combination with the 
innovation adoption curve showed that a physician’s positive relationship orientation 
and active interaction was reflected in the early adoption of new drugs. It demonstrated 
that product advantage and personal interest of physicians as accelerating adoption 
factors. In comparison, the negatively oriented and passively interacting physicians 
adopted new drugs later and did so based on evidence- and experience-based reasoning 
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and the opinions of colleagues. The interlinkages that were identified contribute to 
medical literature focusing on the prescribing behaviour of physicians since this study 
bridges their attitudes toward the pharmaceutical industry and their prescribing 
behaviour instead of investigating them as separate topics (Manchanda and Honka, 
2005). This study also makes the physician-pharmaceutical industry relationship the 
focal point when studying physicians’ adoption patterns as previous studies have 
focused on their relationships with professional colleagues (Coleman et al., 1957) and 
patients (Mason, 2008). Moreover, the findings contribute to the previous studies, 
which have limited their focus to the linkage between the attitudes and interaction of 
physicians with the pharmaceutical industry (Doran et al., 2006), or the linkage between 
the interaction of physicians and new drug introduction (Buban et al., 2001; De Ferrari 
et al., 2014). 
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6 Conclusions 
?
6.1 Theoretical implications 
?
The first contribution concerns the role and relative direct impact of a 
company’s strategic orientations on launch performance. The findings demonstrate that 
a company’s relationship orientation is the strongest predictor of launch performance 
compared to the other studied strategic orientations. As the vast majority of NPL studies 
have focused on the market orientation (Langerak, 2003; Kirca et al., 2005; van Raaij 
and Stoelhorst, 2008), this thesis extends our knowledge on the role of strategic 
orientation in launch performance (cf. Langerak, 2003; Langerak et al., 2004; Talke and 
Hultink, 2010a; Mu and Di Benedetto, 2011). More specifically, this study broadens the 
established positive link between a company’s relationship orientation and general 
business performance (Yau et al., 2000; Sin et al., 2002; Sin et al., 2005a; Stewart et al., 
2012; Salojärvi et al., 2015) to launch performance, including customer acceptance and 
financial launch performance measures. Thus, a company’s relationship orientation is 
deemed a complementary key success determinant in the launch of a new product. 
The second contribution relates to the relationship orientation from the buyer’s 
perspective. The results deepen our current understanding of the relationship orientation 
of physicians toward the pharmaceutical industry. The physicians’ relationship 
orientation was categorized as positive, neutral or negative. Furthermore, the 
physicians’ desire to develop professionally, their dependence on novel information as 
well as the competence and behaviour of the sales representatives were the key 
antecedents of the physicians’ relationship with the pharmaceutical industry as a whole. 
In addition, by studying the concept of relationship orientation from a buyer’s 
perspective, links are made to the findings of business literature, which is important as 
Palmatier et al. (2008) have demonstrated that a buyer’s relationship orientation 
determines the effectiveness of relationship marketing. 
The third contribution of this study concerns the alternative theoretical 
mediating mechanisms for explaining how a company’s strategic orientations affect 
launch performance, especially customer acceptance. The results showed that all the 
studied orientations affected customer acceptance through different mechanisms. More 
specifically, the study demonstrated that accumulated market-based assets represent a 
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powerful relational mediator that works alongside the product advantage to link a 
company’s orientations and launch performance. Therefore, the accumulated market-
based assets provide a relational aspect on the study of launch performance by 
examining it through established customer relationships (cf. Srivastava et al., 1998; 
Kirca et al., 2005; Grewal et al., 2009). This finding widens the focus of the existing 
NPL research, which has concentrated on product advantage as a central mediator in 
explaining how a company’s market-oriented organizational culture affects launch 
performance (Langerak et al., 2004).  
Furthermore, this study contributes to the existing NPL studies by providing 
new detailed insights into key activities in effective implementation of a company’s 
abstract relationship-oriented organizational culture into practice in the NPL context. 
The results revealed that the relationship orientation is a central driver of systematic 
sales force management and relationship marketing in the NPL setting. More 
specifically, sales force management plays a key role in transforming a relationship-
oriented culture into relationship marketing activities. Furthermore, relationship 
marketing activities mediate the performance effects of the relationship orientation and 
sales force management. 
The fourth contribution concerns the individual determinants of NPL success at 
the different stages of a product’s lifecycle in the pharmaceutical industry setting. The 
findings demonstrate the diversity of the determinants of success. Whereas financial 
NPL success is driven by strategic choices and tactical decisions, the relationship 
approach is vital for fostering customer acceptance at different phases of the innovation 
diffusion. In particular, product advantage and relationship marketing activities play a 
significant role in achieving the acceptance of KOLs in the early phase of a NPL, while 
the accumulated market-based assets and relationship-oriented organizational culture 
largely determine the acceptance of a new product by the majority of other target 
customers in the later phase. Based on these findings, this study provides a holistic 
overview of the key determinants of NPL success (Stros and Lee, 2014) and links them 
to the different stages of the product lifecycle by utilizing the theory of innovation 
diffusion (Rogers, 2003), thus contributing to the existing pharmaceutical marketing 
literature. 
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The fifth contribution relates to the physician-pharmaceutical industry 
relationship and interaction in order to build a mutually meaningful and beneficial 
collaboration between physicians and pharmaceutical companies, and how this 
relationship is reflected in the introduction of a new drug. The findings revealed that a 
physician’s positive relationship orientation and active interaction results in the early 
adoption of new drugs that have a product advantage. Additionally, if a physician has a 
personal interest in the adoption of a new drug this will also accelerate its adoption. In 
comparison, negatively oriented and passively interacting physicians will adopt a new 
drug later on, and do so based on research evidence- and experience-based reasoning 
and the opinions of their colleagues. In combination with the theory of innovation 
diffusion (Rogers, 2003), this study broadened our current understanding of the 
physician-pharmaceutical relationship (Doran et al., 2006) and demonstrated how the 
relationship orientation of physicians is reflected in the introduction of a new product in 
the medical B2B context. Furthermore, the study demonstrated that the relationship 
between physicians and the pharmaceutical industry has developed from being ethically 
precarious and having non-professional related personal benefits toward becoming a 
more sustainable collaboration (cf. Moynihan, 2003; Brennan et al., 2006; Angell, 
2009). 
In conclusion, this thesis contributes to the existing NPL literature by providing 
a holistic and comprehensive overview on the key determinants of NPL success and by 
generating new empirical evidence on the importance of a relationship approach in the 
pharmaceutical NPL context (Table 10). The overall results are aligned with pioneering 
studies on the importance of networks in the commercialization of an innovation (e.g. 
Story et al., 2011; Aarikka-Stenroos et al., 2014; Aarikka-Stenroos and Lehtimäki, 
2014; Sandberg and Aarikka-Stenroos, 2014). In particular, the findings from both the 
seller’s and the buyer’s perspectives call for a relationship approach that complements 
the traditional sales and marketing approach in the pharmaceutical NPL setting. 
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Table 10. A summary of the answers to the research questions 
No. Research question Answer 
 What is the role and 
impact of the 
relationship approach in 
NPL success?  
The relationship approach has a significant impact on 
launch performance in the pharmaceutical NPL context 
complementing the traditional sales and marketing 
approach.  
1 What is the role and 
relative impact of the 
alternative strategic 
orientations of a 
company on launch 
performance? 
A company’s relationship orientation has the strongest 
positive impact on launch performance in comparison to 
market and product orientations. 
2 How are the attitudes of 
physicians toward the 
pharmaceutical industry 
reflected in their 
relationship orientation 
and what are the key 
antecedents of their 
relationship orientation?  
The attitudes of physicians toward the pharmaceutical 
industry are reflected in their relationship orientation being 
positive, neutral or negative. The physicians’ desire to 
develop professionally, their dependence on novel 
information and the competence and behaviour of the sales 
representatives were the key antecedents of the physicians’ 
relationship to the pharmaceutical industry. 
3 How are a company’s 
abstract strategic 
orientations transformed 
into launch performance? 
Accumulated market-based assets mediate the impact of 
market and relationship orientations on customer acceptance, 
whereas the impact of product orientation is mediated 
through product advantage. Sales force management and 
relationship marketing activities mediate the relationship 
orientation’s impact on launch performance. 
4 What are the key 
determinants of NPL 
success, how do they 
affect launch 
performance, and how do 
they link to the 
innovation adoption 
curve? 
 
Whereas financial performance is driven by strategic choices 
and tactical decisions, the relationship approach is vital in 
fostering customer acceptance at different phases of the 
innovation diffusion. In particular, product advantage and 
relationship marketing activities have a significant role in 
achieving the acceptance of KOLs in the early phase, while 
the accumulated market-based assets and relationship-
oriented organizational culture largely determine acceptance 
by the majority of the other target customers in later phases.  
5 How can a mutually 
meaningful and 
beneficial collaboration 
between a physician and 
the pharmaceutical 
industry be built, and 
how is this relationship 
reflected when a new 
drug is introduced? 
The physician-pharmaceutical industry relationship has 
developed from being ethically precarious and having non-
professional personal benefits in the direction of a more 
sustainable collaboration. A physician’s positive relationship 
orientation and active interaction can result in the early 
adoption of new drugs with product advantage. A physician’s 
personal interest in a new drug will also accelerate the 
adoption of a new drug. In comparison, negatively oriented 
and passively interacting physicians will adopt a new drug 
later and do so based on research evidence- and experience-
based reasoning and the opinions of their colleagues. 
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From the methodological perspective, this study demonstrated the valuable 
combination of both quantitative and qualitative research strategies and both 
perspectives of the buyer-seller dyad. In addition, two different quantitative analytical 
methods improved the methodological triangulation, allowing for the better 
interpretation and validation of the results. Furthermore, PLS-R/TP employing 
selectivity ratios proved to be a useful method for identifying and ranking the most 
important determinants that contribute to launch performance. Actually, this technique 
is widely used in variable selection and model interpretation in a diversity of biomarker 
analyses, pharmaceutical product development and manufacturing related applications 
(e.g. Gabrielsson et al., 2002; Rajalahti et al., 2010; Zomer et al., 2010), but this study 
broadens the method’s usability to sales and marketing analyses. Lastly, the researcher 
developed the design of the graphics to better illustrate the selectivity ratios. 
 
6.2 Managerial implications 
 
This study calls for a relationship approach to complement the traditional 
approach to the research of NPLs in order to effectively enhance the launch of new 
products through relationship-oriented sales and marketing activities. The study 
provides evidence from the perspectives of both buyers and sellers, demonstrating that 
the relationship approach is centrally connected to customer acceptance and success in 
the NPL context. A pharmaceutical product launch should focus on appropriate 
relationship marketing activities conducted in a timely manner to achieve the 
acceptance of the target customers. The proper targeting of these activities is of 
considerable importance since major changes in the healthcare environment, such as 
pressures for cost savings, difficulties in gaining access to physicians, and tightening 
regulations on promotion, call for attention to be paid to the effectiveness of the 
pharmaceutical sales force (Ruzicic and Danner, 2007; Fraenkel, 2011). As the sales 
force operation has been considered the most expensive pharmaceutical marketing 
activity (Black, 2005), the relationship approach offers a novel perspective on 
traditional sales and marketing and provides the required effectiveness (cf. Ruzicic and 
Danner, 2007; Terblanche, 2008). 
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6.2.1 Building a relationship-oriented organizational culture  
 
This study provides several important and practical managerial implications for 
enhancing the launch of new products from the perspective of a company’s strategic 
orientations. As our results indicate, managers who are responsible for NPL should 
recognize that a company’s various orientations play different roles in driving launch 
performance. As a restrictive mindset within a company has been recognized as an 
internal diffusion barrier to the commercialization of radical innovations (Sandberg and 
Aarikka-Stenroos, 2014), strategic orientations, which are tightly related to a company’s 
organizational culture, can thus help to overcome this barrier and enhance launch 
success. 
The results indicate that at least in the highly intensive R&D businesses, such as 
pharmaceuticals, an in-depth understanding of customer needs and competitors does not 
necessarily result in the development of highly superior products. Nevertheless, a 
company’s internal focus on innovation and its endeavors to offer superior products to 
the market is central for product advantage.  
In comparison to a company’s internal product-centered focus, an external 
market-oriented and especially a relationship-oriented organizational culture is a driver 
for NPL success. Since a company’s relationship orientation was found to be the most 
important strategic orientation for success when launching new products, it should be 
perceived as a complementary approach to the dominant market orientation. The desire 
to engage in establishing and developing strong and long-term relationships has a 
powerful impact on success when launching new products. A relationship-oriented 
company is willing to invest time, effort, finances and resources in building stronger 
customer relationships and is committed to maintaining valued customer relationships. 
Furthermore, a relationship-oriented company treats its customers with empathy and 
reciprocity, and builds trust in its business practices. Therefore, companies should focus 
on creating an organizational culture that puts customer and key stakeholder 
relationships at the core of their strategic thinking.  
Top-level managerial attention is crucial for forming the relational mindset in 
the company and transferring it to lower levels of an organization and across its 
departments. Therefore, the top management of a pharmaceutical company needs to 
devote sufficient resources to creating relational frontline sales as well as marketing 
? 76 
activities relating to NPL such as customer appointments, KOL involvement and co-
operation in professional training. That should be done to communicate the importance 
of relationships to middle-level sales management and to ensure, for example, that sales 
management goals and rewards are accordingly aligned with activities for establishing 
long-term customer relationships (cf. Fraenkel, 2011; Kuester et al., 2012). In addition 
to a company’s frontline sales and marketing staff, top management could demonstrate 
the importance of relationships by visiting key customers personally and by prioritizing 
activities related to customer relationship in all operations.  
Balancing a company’s strategic orientations can also impact on measures used 
for monitoring business performance. While product-oriented companies may focus on 
product-based sales and profitability measures, market-oriented companies may favor 
measures related to market share, market trends and competitors. Instead, a relationship-
oriented company could utilize share-of-wallet type of measures – in addition to the 
conventional measures, in order to differentiate between the potential, the sales volumes 
and the profitability of key customers, and to target sales and marketing activities 
appropriately.  
 
6.2.2 Managing new product launch as a relational activity 
 
This study demonstrates that NPL can be effectively managed as a relational 
activity. The relationship-oriented organizational culture acts as a necessary prerequisite 
for the relationship approach and its benefits will not be realized unless attention is paid 
to the details of sales force management and relationship marketing activities. If a 
company wants to invest in activities that aim to establish, maintain and leverage 
customer and stakeholder relationships in a real-life NPL context, systematic sales force 
management is essential for their effective implementation. This implies that the 
outcomes of the relationship approach cannot be realized as a pure management 
philosophy, but need to be directly linked to changes in sales and marketing activities.  
This study guides how pharmaceutical companies should improve the 
management of the behavioral aspects of their frontline sales and marketing activities 
based on the physicians’ expectations of their collaboration with the pharmaceutical 
industry at its best. In particular, sales force managers should ensure the appropriate and 
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professional behavior and proper course of action of sales representatives. Personnel of 
the pharmaceutical companies that work in the customer interface should interact 
openly and reciprocally, providing accurate and objective information instead of 
superficial and one-sided information. All these aspects can help to increase trust and 
satisfaction among physicians (Krumholz et al., 2007), especially when the worst 
experiences of the physician-pharmaceutical industry collaboration, which occurred in 
the 1980s and 1990s, still concern physicians.  
The different degrees of the physicians’ relationship orientation toward the 
pharmaceutical industry help companies to streamline their relationship-focused sales 
and marketing activities. In practice, the pharmaceutical companies should target these 
activities to the most responsive customer groups by taking into account the level of 
relationship orientation of the physicians. This would help the companies to avoid 
ineffective sales and marketing activities and help physicians to use their time and 
limited resources more effectively.  
From a competence development perspective, this means that it is essential to 
put effort into relational competences, especially in case of personnel operating in 
frontline activities. The average training and competence level of the lower-level sales 
and marketing personnel needs to increase as sales and marketing activities that take a 
relationship approach require more insight, content, and emotional intelligence than the 
more mundane tasks of product sales and marketing. Purely product-based training 
alone is insufficient in present-day launches due to the wide range of stakeholders 
involved (cf. Talke and Hultink, 2010). 
Furthermore, to enhance launch performance, sales and marketing activities 
aimed at creating relationships should be integrated (cf. Ingram, 2004; Hughes et al., 
2012). Interestingly, commonly executed business operations currently include the 
outsourcing of the sales force and the centralizing of country-specific marketing units to 
regional level headquarters, while sales are performed country-by-country. Although 
these operations are justified by the need for cost-savings and flexibility, they are at 
odds with a relational approach that highlights the maintenance of strong relationships, 
which is a local activity in the buyer-seller interface.  
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6.2.3 Dealing with a diversity of success drivers 
 
The identified differences between the key success drivers at the different 
phases of the product lifecycle provide several concrete implications for the effective 
launch of a new pharmaceutical product. Most importantly, all personnel responsible for 
launching new products should note the distinction between the factors driving 
customer acceptance versus financial launch performance.  
In the early phase of a product launch, the identification and involvement of 
KOLs is crucial because their rapid acceptance of a drug is critical for success 
(Corstjens et al., 2005). Preferably, close interaction should be initiated during the drug 
development phase (Sandberg, 2002), or even earlier in the drug design phase because 
the link between customer relationship management and new product development has 
been found to be a critical factor for increasing company performance (Ernst et al., 
2010; Ernst et al., 2011). Utilizing the expertise of a KOL early enough, for example, in 
formulary decisions (cf. Groves et al., 2002), could help companies to avoid difficulties 
when competing in a market with low margins.  
As seen from the perspective of physicians, the early adopters prescribe a new 
drug based on its product advantage over a competitor’s product and their personal 
interest. Thus, the early involvement of a KOL could support a company in trying to 
achieve a customer’s acceptance in this early market segment. This buyer’s perspective 
in the adoption of a new product emphasizes the key role of the opinions of colleagues 
and opinion leaders, albeit this phenomenon has been criticized in the medical 
community (Moynihan, 2008). In addition, relationship marketing activities including 
early market pro-active activities, such as building market awareness to arouse interest, 
product-related high-quality education, and collaborative communication (Smith, 2009), 
are vital for success. However, regulatory approval aspects and national codes of 
practice need to be taken into account when planning and executing relationship 
marketing activities directed toward physicians and other healthcare professionals. 
The prescribing behavior of later adopters is based on evidence- and experience-
based reasoning. In this mainstream market segment, the roles of pricing and a 
product’s cost-benefit ratio are emphasized. Thus, the strategic choices, such as 
comprehensively gathered market intelligence and a clearly defined launch strategy as 
well as tactical decisions concerning pricing policy and appropriate price level, 
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positively affect financial success. The opinions of physicians’ colleagues have a strong 
impact on the introduction of a new drug, underlining the power of opinion as an 
accelerating or delaying factor in new product adoption (cf. Pitt and Nel, 1988; 
Palmatier et al., 2006; Jaakkola and Renko, 2007; Chiesa and Frattini, 2011). Hence, 
positive word-of-mouth should be supported with appropriate marketing mix activities, 
such as promotion and marketing communications and a proficiently executed 
marketing plan. These strategic choices and tactical decisions together with a deeper 
understanding of physicians’ prescribing behavior should help the pharmaceutical 
companies to maximize the financial success of a NPL. 
In the later phase of a product launch, management should also focus on the 
proper leveraging of a company’s market-based assets, which will have been 
accumulated during a company’s operation in the market. A company’s market-oriented 
culture and especially its relationship-oriented organizational culture can help it to build 
and accumulate market-based assets by strengthening customer awareness and 
preference regarding the company’s brand and by extending the existing customer base 
and supporting customer loyalty, thus paving the way for successful launches though 
established relationships (cf. Aarikka-Stenroos et al., 2014). Therefore, managers 
should identify their organization’s existing but underutilized market-based assets and 
further understand how these accumulated assets could be employed and maximized in 
the planning and execution of a product launch.  
In practice, the importance of market-based assets can be seen in the context of 
small pharmaceutical companies focusing on innovative product development. Due to a 
lack of market-based assets, these companies are not able to launch their new products 
on the actual market themselves and end up licensing the products to larger and more 
established pharmaceutical companies, which are in a better position to succeed in a 
NPL by leveraging their accumulated market-based assets. 
Whereas the commercialization of radical innovations is an iterative process 
comprising transits back and forth between strategic marketing decision-making, market 
creation and preparation, and sales creation and development in some industry sectors 
(Aarikka-Stenroos and Lehtimäki, 2014), the nature of a NPL in the pharmaceutical 
industry (with its long development times and tight approval procedures) calls for a 
more straightforward approach to the launch process. From a relationship perspective it 
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means that company relationships need to be established when launching new products. 
As has been pointed out, undeveloped networks are one of the key external barriers for 
successful innovation diffusion (Sandberg and Aarikka-Stenroos, 2014), while properly 
developed networks may facilitate the adoption of a new product and further its success 
in the market (Aarikka-Stenroos et al., 2014; Chiesa and Frattini, 2011). Therefore, 
building a surrounding network, not only for customers, but also for other key 
stakeholders should be seen as a market-based asset.  
 
6.2.4 Implications for policymakers 
 
This study carries implications for policymakers regarding the understanding of 
the perspective of physicians and their needs for a mutually meaningful and beneficial 
relationship with the pharmaceutical industry. Novel knowledge might support 
policymakers in their attempts to balance better requirements for increased marketing 
restrictions with the primary needs of physicians in their cooperation with 
pharmaceutical companies (cf. Stossel, 2007). High-quality collaboration, at its best, 
supports a physician’s professional development, enabling the needs of physicians to be 
better catered to, and, as a consequence, the needs of patients. It can also help to relieve 
the pressure on the limited resources of physicians, freeing up more of their time and 
budget for their key duties.  
In addition, novel knowledge on early versus late adopters and their varying 
prescribing rationales might support policymakers in planning and building budgets, 
guidelines and incentive schemes. Incentive schemes for physicians may serve to 
optimize healthcare resourcing and clinical practices, especially when the financial 
challenges of public economics are increasing (Mossialos et al, 2005). Furthermore, 
from an educational perspective, policymakers should recognize the supporting role of 
the pharmaceutical industry in the continuous medical education and professional 
postgraduate studies of physicians. This aspect should also be taken into account when 
developing rules for physician-pharmaceutical industry collaboration. 
One might ponder the ethical aspects of the relationship approach in the 
pharmaceutical NPL context. On the other hand, this thesis responds to this criticism by 
providing a deeper understanding of the physician-pharmaceutical industry relationship 
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and the physicians’ need for mutually meaningful and beneficial collaboration with the 
pharmaceutical companies. Furthermore, from society’s perspective, it is crucial that the 
launch of a new drug is well managed as it enables society to get the most out of R&D 
spending, and allows the pharmaceutical industry to invest more in the development of 
new drugs. 
?
6.3 Avenues for future research 
?
The purpose of this thesis was to obtain a holistic and comprehensive overview 
of the key determinants of NPL success in the pharmaceutical industry. Special 
emphasis was put on the largely neglected relationship approach. In addition to the 
valuable theoretical contributions and the concrete managerial implications, this study 
has some limitations, which offer avenues for future research.  
As the study was executed in one specific industry sector and in one country, 
future studies need to consider other industries that have different degrees of R&D 
intensity and/or a relational nature as well as various geographical areas in order to 
enable cross-country comparisons and the further generalization of results. The strength 
of the identified links between the key determinants and the launch performance 
suggests that the relational approach may impact on launch performance in other 
business and marketing contexts dominated by novel offerings and solutions carrying a 
risk for purchasers. In these contexts, the lowering of innovation diffusion barriers by 
working closely with key stakeholders will be of prime importance. 
This study focused on the selected key mediators between a company’s strategic 
orientations and launch performance. Future studies may explore other possible 
mechanisms through which a company’s organizational culture is transformed into 
practice. As the product-oriented approach has dominated the pharmaceutical industry, 
an apparently vast knowledge about past experiences and processes has been 
accumulated in its companies. In agreement with the studies on market-based assets, 
these “technology-based assets” could be a potential mediator in addition to the widely 
studied concept of product advantage.  
Furthermore, the examining of the potential contingencies and moderating 
effects of the identified key relationships, and the adoption of a longitudinal approach 
are encouraged. For example, it would be interesting to examine how digitalization and 
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online relationship marketing activities affect the physician-pharmaceutical industry 
relationship and the pharmaceutical companies’ ways of operating at the customer 
interface. As online tools and applications are becoming increasingly available, future 
studies could focus on a combination of marketing and information technology 
cooperation, similarly to the commonly studied concepts of cross-functional 
coordination (e.g. Di Benedetto, 1999) and cooperation between marketing and R&D 
(e.g. Ernst et al., 2010). 
This study focused on the physician-pharmaceutical industry relationship, 
illustrating the buyer-seller dyad. As pointed out, several different stakeholders are 
needed in order to get a new drug to market. Thus, future studies should broaden the 
focus to the other key relationships of different stakeholders in the pharmaceutical NPL 
context. Furthermore, future studies could examine the implementation of a company’s 
relationship orientation in a deeper way by use of qualitative research settings. 
From buyer’s perspective, the aim of this study was to obtain a novel and deeper 
understanding of the physician-pharmaceutical industry relationship instead of making 
the results widely generalizable. Once the key factors and mechanisms for mutually 
meaningful physician-pharmaceutical industry collaboration and new drug introduction 
have been identified, future qualitative and larger-scale quantitative studies on this 
relationship and its role in the adoption patterns of physicians could extend the research 
focus across different countries and healthcare systems. For instance, further studies 
could investigate how a physicians’ relationship orientation and the intensity of their 
interaction associates with the quality, quantity and the cost of their prescribing 
(Spurling et al., 2010) or the ending of drug therapy (Groves et al., 2002). Also future 
studies could focus on other healthcare professionals, their relationship orientation 
toward the pharmaceutical industry and its influences. 
From a wider perspective, a physician’s prescribing pattern does not illustrate 
the whole adoption of a new drug. Physicians typically choose a drug by prescribing it, 
but in the full adoption of a new drug the opinions and experiences of the end-users – 
the patients – should be taken into account (Jaakkola and Renko, 2007). Hence, further 
studies could include the perspective of patients as second-level adopters. 
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Appendices 
Appendix 1. Questionnaire 
SURVEY ON DETERMINANTS OF NEW PRODUCT LAUNCH SUCCESS 
 
I) BACKGROUND INFORMATION 
 
1.  In which function/department you are working in the organization?  
a. Business development 
b. Management (e.g. Managing Director or Business Unit Director) 
c. Market access/Pricing 
d. Market research/intelligence 
e. Marketing 
f. Medical  
g. Sales 
h. Other, please specify 
 
2.  What is your position in the organization?  
a. Director 
b. Manager 
c. Other 
 
2a. Please specify your working title in the organization? 
a. Business Unit Director 
b. Commercial Director 
c. Managing Director 
d. Marketing Director 
e. Medical Director 
f. Sales Director 
g. Sales and Marketing Director 
h. Vice President 
i. Other Director, please specify 
 
        2b. Please specify your working title in the organization? 
a. Brand Manager 
b. Business Development Manager 
c. Business Unit Manager 
d. Key Account Manager 
e. Market Access Manager 
f. Marketing Manager 
g. Product Manager 
h. Project Manager 
i. Sales and Marketing Manager 
j. Sales Manager 
k. Other Manager, please specify 
 
  2c. Please specify your working title in the organization? 
a. Medical / Scientific Advisor 
b. Medical Scientific Liaison 
c. Other, please specify 
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3. How long experience (in years) you have in the pharmaceutical industry? 
a. 1 – 5 years 
b. 5 – 10 years 
c. 10 – 15 years 
d. 15 – 20 years 
e. > 20 years 
 
4. How familiar you are with the new product launch related practices in your organization? 
f. Very familiar 
g. Quite familiar 
h. Not at all familiar 
 
The following questions are related to the launched medicinal (drug) product characteristics. 
Please focus on a single recently (maximum 5 years ago) completed launch of a new 
medicinal (drug) product requiring marketing authorization in your organization that you 
are most familiar with. 
  
5. Was the launched product (select only one option) 
a. Prescription (Rx) drug 
b. Over-the-counter (OTC) drug 
 
6. Was the launched product (select only one option) 
a. Proprietary drug 
b. Generic drug 
c. Other 
  
7. What was (were) the primary target customer group(s) for the launched product at the 
time of launch?  
a. General practitioners/primary health care 
b. Specialists/specialists health care  
c. Both GPs and specialists 
d. Consumers directly 
e. Pharmacists 
f. Veterinaries 
 
8. What kind of innovation the launch product represented at the time of launch? (select 
only one option) 
a. Major/radical innovation (e.g. totally new medical entity) 
b. Minor/incremental innovation (e.g. any modification to the product available in 
market) – If yes, please select one or more of the following options: 
i. New combination product 
ii. Transfer from Rx to OTC 
iii. Generic product 
iv. Parallel import product 
v. Line-extension of indication 
vi. New dosage/strength 
vii. New formulation 
viii. New route of administration 
ix. New flavor 
x. New packaging  
xi. Other 
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9. What was the stage of the launched product novelty at the time of launch? (select only 
one option) 
a. Product was new to the market (i.e. There was not a corresponding product on 
the market)  
b. Product was new to the company (i.e. There was a corresponding product on the 
market but the company did not have a corresponding product)  
 
10. Where the product was launched? 
a. Product was launched only in Finland 
b. Product was launched as a part of global/European/Scandinavian wide launch 
 
11. What was the year of the product launch? 
 
12. Was the launched product first in the market? (E.g. was the proprietary drug first in its 
therapy class or was the generic drug first generic in its therapy class?) 
a. Yes 
b. No 
 
13.  What was the launched product’s sales target (in million euros) within 12 months 
from the launch in Finland?  
a. < 0.1 million euros 
b. 0.1 – 0.5 million euros 
c. 0.5 – 1 million euros 
d. 1 – 2 million euros 
e. > 2 million euros 
 
II) DETERMINANTS OF NEW PRODUCT LAUNCH SUCCESS 
 
The following sets of statements will examine the determinants of the new product launch 
success. Please express your opinion on these determinants by assessing the following 
statements in scale from 1 to 7 in where 1 means you strongly disagree, 2 means you partly 
disagree, 3 means you slightly disagree, 4 means you neither agree or disagree, 5 means you 
slightly agree, 6 means you partly agree and 7 means you strongly agree. Please answer from 
the perspective of the medicinal (drug) product that you have selected earlier.  
 
IIa) DOMINANT APPROACH 
 
Market orientation related statements  
 
The statements of this section focus on company’s overall market related mindset. Please 
response according to how well the following statements held true at the time of selected 
product launch.  (1 = strongly disagree; 7 = strongly agree) 
 
1. We focused on gathering market intelligence pertaining to current and future customer 
needs ................................................................................ 1 2 3 4 5 6 7 
 
2. All of our functions – not just sales and marketing – were responsive to the gathered 
market intelligence pertaining to current and future customer needs 
  ......................................................................................... 1 2 3 4 5 6 7 
 
3. Our company’s objectives were driven primarily by customer satisfaction 
 ......................................................................................... 1 2 3 4 5 6 7 
 
4. We measured customer satisfaction systematically and frequently  
 ......................................................................................... 1 2 3 4 5 6 7 
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5. Our business strategies were driven by our beliefs about how we can create greater value 
for our customers ............................................................. 1 2 3 4 5 6 7 
 
6. Our strategy for competitive advantage was based on our understanding of our 
customers’ needs ............................................................. 1 2 3 4 5 6 7 
 
7. Our top management regularly discussed competitors' strengths and strategies  
 ......................................................................................... 1 2 3 4 5 6 7 
 
8. We targeted customers and customer groups in which we had or were able to develop a 
competitive advantage ..................................................... 1 2 3 4 5 6 7 
 
9. We had the ability to respond rapidly to competitors' actions  
 ......................................................................................... 1 2 3 4 5 6 7 
 
10. Information on customers, marketing successes and marketing failures were 
communicated across functions in the business .............. 1 2 3 4 5 6 7 
 
11. All of our managers understood how everyone in our business can contribute to creating 
customer value  ................................................................ 1 2 3 4 5 6 7 
 
Product characteristics related statements 
 
The three first statements of this section focus on company’s overall product related mindset. 
Please response according to how well the following statements held true at the time of selected 
product launch. (1 = strongly disagree; 7 = strongly agree) 
 
12. We believed that customer's perception of product superiority with respect to quality,  
cost-benefit ratio, or function relative to competitors is the key to new product launch 
success ............................................................................. 1 2 3 4 5 6 7 
 
13. We believed that product innovativeness and uniqueness are the keys to new product 
launch success ................................................................. 1 2 3 4 5 6 7 
 
14. We endeavored to offer the best products in our industry 
 ......................................................................................... 1 2 3 4 5 6 7 
 
The last statements of this section focus on the selected launched drug product. 
 
15. The launched product offered unique benefits for customers  
 ......................................................................................... 1 2 3 4 5 6 7 
 
16. The launched product was highly innovative .................. 1 2 3 4 5 6 7 
 
17. The launched product was radically different from competitor products   
 ......................................................................................... 1 2 3 4 5 6 7 
 
18. The launched product was superior (e.g. in terms of quality, cost-benefit ratio and/or 
functioning) to competing products ................................ 1 2 3 4 5 6 7 
 
19. The launched product fulfilled a clear unmet market need  
 ......................................................................................... 1 2 3 4 5 6 7 
 
20. The launched product was compatible with customer's values and previous experiences  
 ......................................................................................... 1 2 3 4 5 6 7 
 
 
 
? 106 
Strategic choices related statements 
 
The statements of this section focus on the strategic aspects of the selected launched drug 
product. (1 = strongly disagree; 7 = strongly agree) 
 
21. Launch objectives and success measures had been clearly defined 
  ......................................................................................... 1 2 3 4 5 6 7 
 
22. Market information (e.g. market studies) regarding the product had been comprehensively 
gathered and utilized in decision-making ........................ 1 2 3 4 5 6 7 
 
23. Launch strategy (e.g. innovative and product advantage strategy; cost oriented strategy) 
had been clearly defined .................................................. 1 2 3 4 5 6 7 
 
24. Market segmentation had been carefully conducted to identify an appropriate target 
market for the launched product  ..................................... 1 2 3 4 5 6 7 
 
25. Product had been carefully positioned for the target market taking into account to all 
relevant competitors ........................................................ 1 2 3 4 5 6 7 
 
26. Timing of the product launch was successful ................. 1 2 3 4 5 6 7 
 
27. Market access strategy (e.g. informing key decision makers who are involved in 
assessment and approval of drugs about clinical, organizational and financial implications 
of introducing the new product) had been well-designed in a timely manner   
 ......................................................................................... 1 2 3 4 5 6 7 
 
Tactical decisions related statements 
 
The statements of this section focus on the tactical aspects of the selected launched drug 
product. (1 = strongly disagree; 7 = strongly agree) 
 
28. Product launch was supported by a well-designed marketing mix (4Ps; product, price, 
promotion and place/distribution)  .................................. 1 2 3 4 5 6 7 
 
29. Product branding was successful ..................................... 1 2 3 4 5 6 7 
 
30. Pricing policy was well-grounded and the price level was considered appropriate (e.g. 
reimbursement was obtained as planned in the case of a prescription drug?  
  ......................................................................................... 1 2 3 4 5 6 7 
 
31. Promotion and marketing communication was well conducted  
 ......................................................................................... 1 2 3 4 5 6 7 
 
32. The whole supply chain (e.g. sales estimates – manufacturing plant – warehouse – 
wholesaler – customer) of the launched product worked smoothly and promptly  
 ......................................................................................... 1 2 3 4 5 6 7 
 
33. Marketing budget and marketing resources were sufficient and their allocation to various 
means and activities was well conducted ........................ 1 2 3 4 5 6 7 
 
34. Marketing plan was executed proficiently ...................... 1 2 3 4 5 6 7 
 
35. Market access activities (e.g. advanced notification documentation, health outcome 
toolkits and implementation tactics) were successfully implemented in a timely manner  
 ......................................................................................... 1 2 3 4 5 6 7 
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Sales force management related statements 
 
The statements of this section focus on sales force management of the selected launched drug 
product. (1 = strongly disagree; 7 = strongly agree) 
 
36. Adequate sales resources had been allocated for the launched product  
 ......................................................................................... 1 2 3 4 5 6 7 
 
37. Sales people had been given a thorough training and were knowledgeable about the 
launched product ............................................................. 1 2 3 4 5 6 7 
 
38. Sales people were motivated and enthusiastic about the launched product 
 ......................................................................................... 1 2 3 4 5 6 7 
 
39. Sales people were held accountable for the targets of the launched product and their 
compensation and/or incentives were aligned with the targets   
 ......................................................................................... 1 2 3 4 5 6 7 
 
40. Sales people’s activity (e.g. processes, practices and techniques) were well controlled and 
managed during the launch period .................................. 1 2 3 4 5 6 7 
 
41. Sales worked closely with marketing to make the launch successful  
 ......................................................................................... 1 2 3 4 5 6 7 
  
IIb) RELATIONSHIP APPROACH 
 
Relationship orientation related statements  
 
The statements of this section focus on company’s overall customer relationship mindset. Please 
response according to how well the following statements held true at the time of selected 
product launch.  (1 = strongly disagree; 7 = strongly agree) 
 
42. In our organization, retaining customers was considered to be a top priority   
 ......................................................................................... 1 2 3 4 5 6 7 
 
43. Our employees were encouraged to focus on customer relationships  
 ......................................................................................... 1 2 3 4 5 6 7 
 
44. In our organization, customer relationships were considered to be a valuable asset  
 ......................................................................................... 1 2 3 4 5 6 7 
 
45. Our senior management emphasized the importance of customer relationships  
 ......................................................................................... 1 2 3 4 5 6 7 
 
46. We believed that establishing and maintaining strong and long-term customer 
relationships is a key to success  ..................................... 1 2 3 4 5 6 7 
 
47. Our company was willing to invest time, effort, spending and resources on building 
stronger customer relationships ....................................... 1 2 3 4 5 6 7 
 
48. Our company was committed to maintain valued relationships with our customers and 
was willing to work at maintaining those ........................ 1 2 3 4 5 6 7 
 
49. Our company treated our customers with empathy (e.g. we saw things from each others 
point of view and cared about each others feelings)  ...... 1 2 3 4 5 6 7 
 
50. Our company treated customer with reciprocity (e.g. we kept our promises in any 
situation and repaid customers’ kindness)  ..................... 1 2 3 4 5 6 7 
? 108 
51. Our company and our customers trusted each others (e.g. we had confidence in each 
others reliability and integrity)  ....................................... 1 2 3 4 5 6 7 
  
Relationship marketing activities related statements 
 
The statements of this section focus on relationship marketing activities conducted for the 
selected launched drug product. 
(1 = strongly disagree; 7 = strongly agree) 
 
52. Our company had close customer interaction during the product development process of 
the launched product (e.g. clinical trials)  ....................... 1 2 3 4 5 6 7 
 
53. Key opinion leaders (KOL) were identified and involved in the product launch  
  ......................................................................................... 1 2 3 4 5 6 7 
 
54. Our company initiated early market pro-activeness activities (e.g. arousal of interest, 
market awareness, involvement of opinion leaders, product education)   
 ......................................................................................... 1 2 3 4 5 6 7 
 
55. Communication with customers was collaborative including frequent sharing of tailored 
information ...................................................................... 1 2 3 4 5 6 7 
 
56. We provided high-quality training (e.g. continuing medical education) for our customers  
 ......................................................................................... 1 2 3 4 5 6 7 
 
57. Sales people and other personnel working in customer interface recognized their roles as 
relationship builders ........................................................ 1 2 3 4 5 6 7 
 
58. Our company had implemented effective key account management (KAM) practices   
  ......................................................................................... 1 2 3 4 5 6 7 
 
59. Relationship related market access activities (e.g. advisory board meeting, activities 
toward decision-makers and payers) were successfully implemented in a timely manner   
 ......................................................................................... 1 2 3 4 5 6 7 
 
60. Customer related conflicts were managed effectively and resolved quickly   
 ......................................................................................... 1 2 3 4 5 6 7 
 
Customer acceptance related statements 
 
The statements of this section focus on customer acceptance of the launched drug product.  
(1 = strongly disagree; 7 = strongly agree) 
  
61. Customers were well aware of the brand of the launched product  
 ......................................................................................... 1 2 3 4 5 6 7 
 
62. Customers preferred the brand of the launched product to competitors’ product brands  
 ......................................................................................... 1 2 3 4 5 6 7 
 
63. The launched product was rapidly accepted by key opinion leaders (KOL)   
 ......................................................................................... 1 2 3 4 5 6 7 
 
64. The launched product was accepted by majority of the target customers  
 ......................................................................................... 1 2 3 4 5 6 7 
 
65. Customers were satisfied with the launched product ...... 1 2 3 4 5 6 7 
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66. Customers were positively referring (word-of-mouth) the launched product to other 
potential customers  ......................................................... 1 2 3 4 5 6 7 
 
67. Our company succeeded to expand product’s demand through relational networking 
among our customers ...................................................... 1 2 3 4 5 6 7 
 
Market-based assets related statements 
 
Before the new product launch success measures, these last statements focus on market-based 
assets accumulated for the company. (1 = strongly disagree; 7 = strongly agree) 
 
68. Customers were well aware of our company brand  ....... 1 2 3 4 5 6 7 
 
69. Customers preferred our company brand to competitors’ company brands  
 ................................................................................................... 1 2 3 4 5 6 7 
 
70. Our company had an extensive existing customer base .. 1 2 3 4 5 6 7 
 
71. Our company had strong prior relationships with our customers   
 ................................................................................................... 1 2 3 4 5 6 7 
 
72. Our customers were loyal to our company  ..................... 1 2 3 4 5 6 7 
?
III) NEW PRODUCT LAUNCH SUCCESS  
 
The following set of questions will clarify success of the selected new medical (drug) product 
launch. Please answer to the questions by assessing them in scale from -5 to +5 in where -5 
means far below the target level and +5 means far above the target level. Please provide your 
opinion both after the first year and after three years from the launch. If you don’t know, please 
leave the individual item empty.  
 
1. How successful was the product launch in meeting its sales target? 
 
After the first year from the launch 
 
Far below  -5   -4   -3   -2   -1   0   1   2   3   4   5  Far above  
sales target       sales target 
 
After three years from the launch 
 
Far below  -5   -4   -3   -2   -1   0   1   2   3   4   5 Far above 
sales target       sales target 
?
 
2. How successful was the product launch in meeting its market share target? 
 
After the first year from the launch 
 
Far below  -5   -4   -3   -2   -1   0   1   2   3   4   5 Far above 
market share target      market share target 
 
After three years from the launch 
 
Far below  -5   -4   -3   -2   -1   0   1   2   3   4   5  Far above  
market share target      market share target
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3. How successful was the product launch in meeting its profitability target? 
 
After the first year from the launch 
 
Far below  -5    -4   -3   -2   -1   0   1   2   3   4   5  Far above 
profitability target      profitability target   
After three years from the launch 
 
Far below  -5   -4   -3   -2   -1   0   1   2   3   4   5  Far above  
profitability target      profitability target
           
4. How would you rate the overall success of your company’s selected product 
launch perceived as a whole? 
 
Launch was  -5   -4   -3   -2   -1   0   1   2   3   4   5  Launch was  
very unsuccessful      very successful 
         
 
IV) QUESTIONS RELATED TO YOUR COMPANY 
 
At the end, please answer to the questions related to your company.  
 
1. Where does the company’s headquarter locate? 
a. In Finland 
b. Outside Finland 
 
2. What is the size of the company in terms of revenue (in million euros) in Finland in 
2011?  
a. < 50 million euros 
b. 50 – 100 million euros 
c. > 100 million euros 
 
3. What is the size of the company in terms of revenue (in billion euros) outside Finland in 
2011?  
a. < 1 billion euros 
b. 1 – 5 billion euros 
c. 5 – 10 billion euros 
d. > 10 billion euros 
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Appendix 2. Characteristics of the respondents in the survey study 
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Appendix 3. Characteristics of the participants in the interview study 
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Appendix 5 Selectivity ratios and confidence intervals for predictor variables 
 
  Financial Success 
Customer Acceptance             
of KOL 
Customer Acceptance             
of Majority of Customers 
  SR CI (p=0.05) SR CI (p=0.05) SR CI (p=0.05) 
Q1 0.006 0.011 0.003 0.006 0.000 0.004 
Q2 0.000 0.002 0.002 0.004 0.000 0.002 
Q3 0.000 0.003 -0.005 0.005 0.002 0.003 
Q4 -0.091 0.020 0.002 0.003 -0.003 0.007 
Q5 0.028 0.009 -0.080 0.029 -0.000 0.004 
Q6 0.062 0.015 0.000 0.004 0.035 0.012 
Q7a 0.043 0.007 0.002 0.003 0.007 0.005 
Q7b -0.020 0.009 0.024 0.017 0.002 0.006 
Q7c 0.000 0.002 -0.001 0.004 -0.012 0.008 
Q7d 0.013 0.005 -0.084 0.026 -0.001 0.004 
Q7e 0.076 0.018 -0.037 0.023 0.012 0.008 
Q7f 0.035 0.007 0.016 0.006 0.029 0.009 
Q8 0.072 0.018 -0.015 0.013 0.036 0.016 
Q9 0.024 0.008 -0.040 0.016 -0.002 0.006 
Q10 -0.252 0.042 0.019 0.014 -0.025 0.014 
Q11 0.004 0.006 0.010 0.013 -0.005 0.007 
Q12 0.022 0.008 -0.073 0.021 -0.014 0.011 
Q13 0.033 0.020 0.031 0.022 0.009 0.012 
C1 -0.091 0.043 -0.009 0.016 -0.087 0.028 
C2 0.056 0.018 0.008 0.014 0.048 0.027 
C3 -0.078 0.025 -0.000 0.006 -0.003 0.006 
MO1 0.165 0.030 0.065 0.037 0.021 0.026 
MO2 0.092 0.024 0.016 0.016 0.068 0.036 
MO3 0.419 0.058 0.052 0.045 0.145 0.061 
MO4 0.291 0.064 0.067 0.047 0.034 0.030 
MO5 0.144 0.027 0.050 0.018 0.077 0.023 
MO6 0.171 0.032 0.134 0.038 0.219 0.043 
MO7 0.090 0.026 0.020 0.019 0.031 0.022 
MO8 0.253 0.047 0.065 0.042 0.170 0.056 
MO9 0.280 0.050 0.028 0.026 0.194 0.074 
MO10 0.096 0.029 0.0672 0.032 0.132 0.049 
MO11 0.168 0.036 0.0555 0.025 0.129 0.050 
PO1 0.083 0.033 0.120 0.031 0.011 0.015 
PO2 0.000 0.009 0.132 0.038 0.000 0.007 
PO3 0.091 0.034 0.056 0.021 0.016 0.015 
RO1 0.068 0.032 0.101 0.051 0.188 0.074 
RO2 0.037 0.024 0.064 0.044 0.147 0.070 
RO3 0.045 0.028 0.071 0.045 0.178 0.075 
RO4 0.016 0.016 0.037 0.030 0.071 0.046 
RO5 0.083 0.036 0.108 0.052 0.224 0.067 
RO6 0.170 0.053 0.217 0.077 0.480 0.145 
RO7 0.081 0.034 0.159 0.063 0.290 0.107 
RO8 0.286 0.074 0.359 0.111 0.708 0.153 
RO9 0.251 0.060 0.241 0.074 0.520 0.096 
RO10 0.334 0.085 0.317 0.091 0.367 0.074 
PA1 0.006 0.013 0.601 0.151 0.091 0.051 
PA2 -0.056 0.024 0.233 0.082 0.003 0.015 
117 
PA3 -0.028 0.017 0.258 0.089 0.003 0.015 
PA4 0.002 0.007 0.455 0.094 0.083 0.039 
PA5 0.049 0.028 0.588 0.140 0.241 0.090 
PA6 0.052 0.018 0.195 0.040 0.157 0.041 
STR1 0.280 0.051 0.037 0.030 0.181 0.075 
STR2 0.427 0.098 0.168 0.076 0.124 0.064 
STR3 0.478 0.073 0.204 0.066 0.388 0.107 
STR4 0.130 0.048 0.306 0.092 0.453 0.094 
STR5 0.163 0.051 0.253 0.073 0.239 0.057 
STR6 0.347 0.076 0.503 0.104 0.599 0.110 
STR7 0.157 0.040 0.241 0.085 0.297 0.095 
TAC1 0.275 0.042 0.007 0.016 0.117 0.056 
TAC2 0.295 0.063 0.222 0.065 0.283 0.074 
TAC3 0.490 0.106 0.041 0.038 0.077 0.036 
TAC4 0.545 0.100 0.151 0.067 0.313 0.119 
TAC5 0.060 0.019 0.048 0.020 0.043 0.019 
TAC6 0.231 0.062 0.237 0.066 0.285 0.078 
TAC7 0.526 0.104 0.156 0.066 0.234 0.094 
TAC8 0.259 0.045 0.042 0.030 0.119 0.059 
SFM1 0.027 0.016 0.169 0.044 0.085 0.028 
SFM2 0.032 0.022 0.252 0.081 0.143 0.054 
SFM3 0.070 0.032 0.370 0.107 0.329 0.088 
SFM4 0.031 0.018 0.145 0.048 0.160 0.043 
SFM5 0.122 0.041 0.115 0.043 0.112 0.046 
SFM6 0.060 0.030 0.084 0.041 0.164 0.044 
RM1 0.004 0.010 0.383 0.113 0.091 0.038 
RM2 0.004 0.007 0.526 0.142 0.123 0.047 
RM3 0.005 0.008 0.488 0.135 0.088 0.040 
RM4 0.094 0.031 0.649 0.120 0.447 0.100 
RM5 0.014 0.012 0.217 0.078 0.077 0.040 
RM6 0.107 0.033 0.358 0.080 0.386 0.080 
RM7 0.041 0.019 0.173 0.049 0.235 0.050 
RM8 0.082 0.022 0.185 0.062 0.148 0.053 
RM9 0.191 0.031 0.196 0.042 0.223 0.042 
MBA1 0.095 0.042 0.079 0.043 0.537 0.139 
MBA2 0.123 0.050 0.203 0.076 0.664 0.163 
MBA3 0.124 0.053 0.133 0.062 0.585 0.145 
MBA4 0.173 0.066 0.334 0.112 1.000 0.220 
MBA5 0.203 0.070 0.425 0.133 0.930 0.210 
CA1 0.061 0.028     
CA2 0.124 0.046     
CA3 0.266 0.056     
CA4 0.368 0.065     
CA5 0.373 0.074     
CA6 0.423 0.077     
CA7 0.627 0.096         
KOL = Key opinion leader; SR = Selectivity ratio; CI = Confidence interval 
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 m
os
t s
ol
d.
 (P
ar
tic
ip
an
t 1
) 
 If
 th
er
e 
w
as
 n
o 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
, w
e 
w
ou
ld
 h
av
e 
no
 n
ew
 m
ed
ic
in
es
. (
Pa
rti
ci
pa
nt
 1
3)
 
N
eg
at
iv
e 
 
(n
=5
; 
23
%
) 
Ph
ys
ic
ia
ns
’ a
tti
tu
de
 w
as
 re
se
rv
ed
, c
rit
ic
al
 a
nd
 d
is
ta
nt
. 
Th
ey
 re
ga
rd
ed
 c
ol
la
bo
ra
tio
n 
an
d 
dr
ug
 m
ar
ke
tin
g 
as
 
un
et
hi
ca
l, 
an
d 
di
st
ru
st
ed
 re
se
ar
ch
 a
nd
 in
fo
rm
at
io
n 
pr
ov
id
ed
 b
y 
th
e 
co
m
pa
ni
es
.  
I f
ee
l t
ha
t t
he
 p
ha
rm
ac
eu
tic
al
 in
du
st
ry
 is
 v
er
y 
[…
] c
le
ar
ly
 a
 c
ap
ita
lis
t o
rg
an
is
at
io
n.
 T
he
y 
ar
e 
m
ak
in
g 
m
on
ey
, a
nd
 th
at
 is
 th
ei
r b
us
in
es
s a
nd
 th
ei
r p
rio
rit
y 
nu
m
be
r o
ne
. (
Pa
rti
ci
pa
nt
 2
) 
 I t
hi
nk
 [t
he
ir]
 m
ar
ke
tin
g 
is
 a
lw
ay
s u
ne
th
ic
al
. [
It 
is
] a
 fa
ct
 th
at
 th
e 
in
du
st
ry
 tr
ie
s t
o 
m
an
ip
ul
at
e 
m
y 
th
ou
gh
ts
 a
bo
ut
 m
ed
ic
in
es
 b
y 
ho
st
in
g 
ev
en
ts
 w
he
re
 it
 sp
en
ds
 m
on
ey
. (
Pa
rti
ci
pa
nt
 6
) 
 I 
do
 n
ot
 l
ik
e 
th
at
 t
he
 p
ha
rm
ac
eu
tic
al
 i
nd
us
try
, f
or
 e
xa
m
pl
e,
 p
la
ys
 s
uc
h 
a 
gr
ea
t 
ro
le
 i
n 
ou
r 
ed
uc
at
io
n 
at
 e
ve
ry
 le
ve
l. 
[…
] I
 a
lw
ay
s 
ha
ve
 a
 b
ad
 c
on
sc
ie
nc
e 
if 
th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
 
is
 sp
on
so
rin
g 
so
m
et
hi
ng
. (
Pa
rti
ci
pa
nt
 1
6)
 
In
te
ra
ct
io
n 
H
ig
hl
y 
ac
tiv
e 
 
(n
=5
; 
23
%
) 
Ph
ys
ic
ia
ns
 h
ad
 a
 g
re
at
 d
ea
l o
f v
ar
yi
ng
 in
te
ra
ct
io
n 
w
ith
 th
e 
ph
ar
m
ac
eu
tic
al
 c
om
pa
ni
es
. T
he
y 
pa
rti
ci
pa
te
d 
sp
on
ta
ne
ou
sl
y 
in
 o
rg
an
iz
in
g 
ed
uc
at
io
na
l 
ev
en
ts
 a
nd
 le
ct
ur
es
, o
r t
he
y 
ac
te
d 
as
 le
ct
ur
er
s i
n 
co
lla
bo
ra
tio
n 
w
ith
 p
ha
rm
ac
eu
tic
al
 c
om
pa
ni
es
. 
 
W
e 
ha
ve
 a
 lo
t o
f c
ol
la
bo
ra
tio
n 
w
ith
 th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
, e
sp
ec
ia
lly
 th
e 
or
ga
ni
si
ng
 o
f 
ed
uc
at
io
na
l e
ve
nt
s. 
(P
ar
tic
ip
an
t 1
2)
 
 I h
av
e 
be
en
 in
 to
uc
h 
w
ith
 th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
 q
ui
te
 a
 lo
t b
ec
au
se
 I 
am
 a
n 
ed
uc
at
or
-
ph
ys
ic
ia
n.
 I
 p
ro
vi
de
 e
du
ca
tio
n 
an
d 
at
 th
e 
m
om
en
t i
t i
s 
al
m
os
t c
om
pl
et
el
y 
sp
on
so
re
d 
by
 th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
. (
Pa
rti
ci
pa
nt
 1
9)
 
A
ct
iv
e 
 
(n
=5
; 
23
%
) 
Ph
ys
ic
ia
ns
 p
ar
tic
ip
at
ed
 in
 th
e 
de
ta
ili
ng
 o
f p
ro
du
ct
s 
pr
om
ot
ed
 b
y 
sa
le
s r
ep
re
se
nt
at
iv
es
, a
nd
 a
t e
du
ca
tio
na
l 
an
d 
ot
he
r e
ve
nt
s o
rg
an
iz
ed
 b
y 
th
e 
ph
ar
m
ac
eu
tic
al
 
It 
is
 g
oo
d 
to
 h
av
e 
th
e 
po
ss
ib
ili
ty
 to
 c
on
ta
ct
 a
nd
 re
qu
es
t p
er
so
na
l e
du
ca
tio
n 
ab
ou
t a
 p
ro
du
ct
. 
(P
ar
tic
ip
an
t 2
) 
 
119 
co
m
pa
ni
es
. T
he
y 
co
nt
ac
te
d 
ph
ar
m
ac
eu
tic
al
 
co
m
pa
ni
es
 o
nl
y 
w
he
n 
ne
ed
ed
 a
nd
 d
id
 n
ot
 a
ct
iv
el
y 
pa
rti
ci
pa
te
 a
ct
iv
el
y 
in
 th
e 
or
ga
ni
zi
ng
 o
f e
du
ca
tio
n 
or
 
an
y 
ot
he
r c
ol
la
bo
ra
tio
n.
  
If
 t
he
re
 i
s 
a 
ne
w
 m
ed
ic
in
al
 p
ro
du
ct
, 
w
hi
ch
 I
 d
on
’t 
ha
ve
 e
xp
er
ie
nc
e 
of
, 
an
d 
th
er
e 
is
 a
 
pr
ob
le
m
at
ic
 c
as
e 
w
ith
 a
 p
at
ie
nt
, 
I 
do
n’
t 
he
si
ta
te
 t
o 
co
nt
ac
t 
th
e 
m
ed
ic
al
 c
om
pa
ny
 o
r 
th
ei
r 
re
pr
es
en
ta
tiv
e.
 (P
ar
tic
ip
an
t 1
0)
 
 [I
nt
er
ac
tio
n 
is
] 
in
te
ns
iv
e 
an
d 
ev
en
 f
rie
nd
ly
 w
ith
 c
er
ta
in
 s
al
es
 r
ep
re
se
nt
at
iv
es
…
 E
du
ca
tio
na
l 
ev
en
ts
 o
rg
an
iz
ed
 b
y 
[th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
] a
re
 s
o 
go
od
 a
nd
 b
ec
au
se
 th
ey
 a
re
 u
su
al
ly
 
fr
ee
 I 
pa
rti
ci
pa
te
 in
 th
em
 a
nd
 w
ou
ld
 li
ke
 to
 g
o 
to
 th
em
 a
ll 
th
e 
tim
e.
 (P
ar
tic
ip
an
t 7
)  
Pa
ss
iv
e 
 
(n
=9
; 
41
%
) 
Ph
ys
ic
ia
ns
 p
ar
tic
ip
at
ed
 in
 th
e 
de
ta
ili
ng
 o
f p
ro
du
ct
s 
an
d 
ed
uc
at
io
na
l e
ve
nt
s o
rg
an
iz
ed
 b
y 
th
e 
ph
ar
m
ac
eu
tic
al
 c
om
pa
ni
es
 b
ut
 th
ey
 re
ga
rd
ed
 th
ei
r 
ro
le
 a
s b
ei
ng
 th
e 
re
ci
pi
en
t o
f i
nf
or
m
at
io
n.
 
[I
 h
av
e 
pa
rti
ci
pa
te
d 
in
] p
ro
du
ct
 d
et
ai
lin
g…
 In
 p
ra
ct
ic
e,
 I’
m
 m
ai
nl
y 
a 
ta
rg
et
 fo
r m
ar
ke
tin
g 
at
 
th
e 
m
om
en
t 
a 
pr
od
uc
t 
is
 l
au
nc
he
d.
 I
 d
o 
no
t 
ha
ve
 a
ny
 d
ire
ct
 c
ol
la
bo
ra
tio
n 
w
ith
 t
he
 
ph
ar
m
ac
eu
tic
al
 i
nd
us
try
 a
s 
su
ch
. 
I 
ha
ve
 n
ot
 t
ak
en
 p
ar
t 
in
 a
ny
 c
lin
ic
al
 t
ria
ls
 o
r 
th
e 
de
ve
lo
pm
en
t o
f m
ed
ic
in
al
 p
ro
du
ct
s. 
(P
ar
tic
ip
an
t 8
) 
 I h
av
e 
ha
d 
lit
tle
 in
te
ra
ct
io
n 
[w
ith
 th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
]. 
It 
is
 li
m
ite
d 
to
 th
es
e 
w
ee
kl
y 
pr
od
uc
t 
de
ta
ili
ng
 [
se
ss
io
ns
] 
th
at
 w
e 
ha
ve
 h
er
e 
in
 t
he
 h
os
pi
ta
l. 
[T
he
 s
al
es
 r
ep
re
se
nt
at
iv
es
] 
de
ta
il 
pr
od
uc
ts
 in
 o
ur
 fi
el
d.
 (P
ar
tic
ip
an
t 1
1)
 
H
ig
hl
y 
pa
ss
iv
e 
 
(n
=3
; 
14
%
) 
Ph
ys
ic
ia
ns
 a
vo
id
ed
 in
te
ra
ct
io
n 
w
ith
 p
ha
rm
ac
eu
tic
al
 
co
m
pa
ni
es
 a
s m
uc
h 
as
 p
os
si
bl
e.
 T
he
y 
ty
pi
ca
lly
 
bl
oc
ke
d 
or
 fa
ile
d 
to
 a
ns
w
er
 c
on
ta
ct
 fr
om
 
ph
ar
m
ac
eu
tic
al
 c
om
pa
ni
es
, a
nd
 a
vo
id
ed
 p
er
so
na
l 
co
nt
ac
t w
ith
 it
s r
ep
re
se
nt
at
iv
es
. 
 
I 
try
 t
o 
av
oi
d 
th
es
e 
si
tu
at
io
ns
 [
in
te
ra
ct
io
n]
, 
bu
t 
I 
am
 f
or
ce
d 
to
 p
ar
tic
ip
at
e 
in
 e
du
ca
tio
na
l 
ev
en
ts
, w
hi
ch
 a
re
 a
t l
ea
st
 p
ar
tia
lly
 sp
on
so
re
d 
by
 th
e 
ph
ar
m
ac
eu
tic
al
 in
du
st
ry
. (
Pa
rti
ci
pa
nt
 6
) 
 I d
on
’t 
pe
rs
on
al
ly
 m
ee
t s
al
es
 re
pr
es
en
ta
tiv
es
 a
t w
or
k 
no
r a
t a
ny
 o
th
er
 ti
m
e.
 (P
ar
tic
ip
an
t 1
8)
 
N
ew
 p
ro
du
ct
 in
tr
od
uc
tio
n 
Im
m
ed
ia
te
 
ad
op
te
rs
  
(n
=3
; 
14
%
) 
Ph
ys
ic
ia
ns
 in
tro
du
ce
d 
a 
ne
w
 d
ru
g 
as
 e
ar
ly
 a
s 
po
ss
ib
le
, e
ve
n 
be
fo
re
 m
ar
ke
tin
g 
au
th
or
iz
at
io
n.
 T
he
y 
w
er
e 
ve
ry
 k
ee
n 
on
 re
se
ar
ch
 d
at
a 
re
la
te
d 
to
 n
ew
 d
ru
gs
 
an
d 
ca
lle
d 
fo
r n
ew
 p
ro
du
ct
s i
n 
ad
va
nc
e.
  
 
I t
en
d 
to
 g
et
 m
y 
in
fo
rm
at
io
n 
fr
om
 s
ci
en
tif
ic
 re
se
ar
ch
, a
nd
 c
om
m
un
ic
at
io
n 
w
ith
 s
ci
en
tis
ts
 a
nd
 
ed
uc
at
or
s 
re
la
te
d 
to
 th
at
 re
se
ar
ch
, a
nd
 it
 c
om
es
 in
 th
is
 [i
nn
ov
at
or
] p
ha
se
 a
nd
 th
e 
w
id
er
 u
se
 o
f 
th
e 
dr
ug
 c
om
es
 la
te
r. 
(P
ar
tic
ip
an
t 3
) 
 W
e 
ar
e 
th
e 
on
es
 w
ho
 tr
y 
th
em
 fi
rs
t. 
I h
av
e 
al
w
ay
s b
ee
n 
un
pr
ej
ud
ic
ed
. (
Pa
rti
ci
pa
nt
 1
9)
 
Ea
rly
 
ad
op
te
rs
  
(n
=9
; 
41
%
) 
Ph
ys
ic
ia
ns
 w
er
e 
w
ill
in
g 
to
 p
re
sc
rib
e 
ne
w
 d
ru
gs
, w
er
e 
in
te
re
st
ed
 in
 th
em
 a
nd
 re
ad
y 
to
 ta
ke
 a
dv
an
ta
ge
 o
f n
ew
 
re
se
ar
ch
 fo
r t
he
 b
en
ef
it 
of
 th
ei
r p
at
ie
nt
s a
t a
n 
ea
rly
 
ph
as
e.
  
 
A
 w
ill
in
gn
es
s 
to
 b
e 
up
-to
-d
at
e 
an
d 
to
 u
til
is
e 
ne
w
 r
es
ea
rc
h 
fo
r 
th
e 
be
ne
fit
 o
f 
pa
tie
nt
s. 
(P
ar
tic
ip
an
t 1
2)
 
 O
ur
 d
ut
y 
in
 t
he
 u
ni
ve
rs
ity
 h
os
pi
ta
l 
is
 t
o 
try
 s
uc
h 
ne
w
 t
hi
ng
s 
an
d 
ga
in
 e
xp
er
ie
nc
e,
 a
nd
 t
o 
di
ss
em
in
at
e 
th
at
 in
fo
rm
at
io
n.
 (P
ar
tic
ip
an
t 1
4)
 
La
te
 
ad
op
te
rs
  
(n
=1
0;
 
45
%
) 
Ph
ys
ic
ia
ns
 d
el
ay
ed
 th
e 
in
tro
du
ct
io
n 
of
 n
ew
 d
ru
gs
 a
nd
 
di
d 
no
t p
re
sc
rib
e 
ne
w
 d
ru
gs
 u
nt
il 
th
ey
 h
ad
 su
ff
ic
ie
nt
 
in
fo
rm
at
io
n 
ab
ou
t t
he
m
 a
nd
 th
ei
r c
lin
ic
al
 p
ro
fil
e.
 T
he
 
ch
ar
ac
te
ris
tic
s o
f c
on
se
rv
at
iv
en
es
s, 
sc
ep
tic
is
m
, 
ca
ut
io
us
ne
ss
 a
nd
 c
rit
ic
al
ity
 d
es
cr
ib
ed
 th
ei
r a
pp
ro
ac
h.
 
 
B
as
ic
al
ly
, 
I 
ha
ve
 a
 r
at
he
r 
co
ns
er
va
tiv
e 
lin
e 
re
ga
rd
in
g 
ne
w
 d
ru
gs
. 
M
y 
co
lle
ag
ue
s’
 e
xp
er
t 
op
in
io
ns
 a
re
 th
e 
on
es
 th
at
 m
at
te
r i
n 
th
e 
lo
ng
 ru
n…
 T
he
 p
ric
in
g 
an
d 
re
im
bu
rs
em
en
t p
ol
ic
y 
ar
e 
fa
ct
or
s w
hi
ch
 im
pa
ct
 a
s w
el
l. 
Th
ey
 h
av
e 
to
 b
e 
ta
ke
n 
in
to
 a
cc
ou
nt
 to
o.
 (P
ar
tic
ip
an
t 9
) 
 I 
do
n’
t p
re
sc
rib
e 
th
em
 [
ne
w
 d
ru
gs
], 
un
le
ss
 I
 h
ea
r 
fr
om
 a
 c
ol
le
ag
ue
 th
at
 it
 h
as
 w
or
ke
d 
w
el
l. 
[…
] I
n 
ce
rta
in
 c
as
es
, i
t h
as
 b
ee
n 
en
te
re
d 
in
to
 th
e 
[o
rg
an
is
at
io
n’
s 
in
te
rn
al
] t
re
at
m
en
t p
ra
ct
ic
e 
120 
th
at
 c
er
ta
in
 d
ru
gs
 a
re
 p
re
sc
rib
ed
. [
…
] S
om
e 
ch
ie
f p
hy
si
ci
an
 h
as
 d
ec
id
ed
 th
at
 th
is
 is
 th
e 
w
ay
 
to
 g
o.
 (P
ar
tic
ip
an
t 2
0)
 
B
ip
ol
ar
 
ad
op
te
rs
  
(n
=1
0;
 
45
%
) 
Ph
ys
ic
ia
ns
 p
re
sc
rib
ed
 n
ew
 d
ru
gs
 b
ot
h 
in
 th
e 
ea
rly
 a
nd
 
la
te
r p
ha
se
s b
as
ed
 o
n 
th
e 
di
ff
er
en
t r
at
io
na
le
s f
or
 
di
ff
er
en
t s
itu
at
io
ns
 w
he
n 
in
tro
du
ci
ng
 n
ew
 d
ru
gs
. 
In
 a
ll 
gy
na
ec
ol
og
y 
re
la
te
d 
m
at
te
rs
 I 
am
 a
t t
he
 fo
re
fr
on
t. 
I h
av
e 
be
en
 th
e 
fir
st
 to
 p
re
sc
rib
e 
th
e 
dr
ug
s 
th
at
 a
re
 la
un
ch
ed
 s
pe
ci
fic
al
ly
 f
or
 m
y 
fie
ld
. B
ut
 w
he
n 
it 
co
m
es
 to
 e
ve
ry
th
in
g 
el
se
 n
ot
 
re
la
te
d 
to
 g
yn
ae
co
lo
gy
, “
I 
fo
llo
w
”.
 I
 a
m
 li
ke
, “
Le
t’s
 s
ee
 w
he
n 
ev
er
yo
ne
 e
ls
e 
ha
s 
tri
ed
 it
”.
 
(P
ar
tic
ip
an
t 1
9)
 
 In
 c
as
es
 o
f 
a 
ne
w
 in
no
va
tio
n,
 I
 h
av
e 
in
tro
du
ce
d 
it 
ra
th
er
 f
as
t. 
B
ut
 if
 it
 [
a 
ne
w
 d
ru
g]
 h
as
 n
o 
cl
ea
r a
dv
an
ta
ge
 c
om
pa
re
d 
to
 s
om
e 
ot
he
r p
ro
du
ct
 a
va
ila
bl
e 
or
 to
 a
 p
ro
du
ct
 w
hi
ch
 I 
pe
rs
on
al
ly
 
ha
ve
 a
 lo
t o
f e
xp
er
ie
nc
e 
of
, I
 d
on
’t 
fe
el
 a
ny
 n
ee
d 
to
 p
re
sc
rib
e 
it.
 (P
ar
tic
ip
an
t 2
0)
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